Author index

A

Aaen, K. 658
Abaterusso, C. 1569
Abe, H. 1276
Abildgård, N. 226
Achenbach, P. 1351
Ackefors, M. 1091
Adu, D. 1108
Agardh, C.-D. 1313
Agardh, D. 1313
Agardh, E. 1313
Ahrén, B. 383, 649, 1099
Alberti, K. G. M. M. 45, 103, 322, 813, 961, 1227
Altomare, E. 1239
Andersen, A. S. 281
Anderson, L. G. 129
Andrén, B. 1603
Andreasen, F. 226
Anfossi, G. 1156
Angelico, M. C. 940
Annibale, B. 677
Aperia, A. 199
Araki, E. 412, 600
Arend den, J. A. C. J. 1562
Armstrong, M. 322
Arner, P. 845, 857, 921
Arrieta, F. J. 22
Asahina, T. 1115
Ashcroft, F. M. 1233
Assad, N. 275
Atsumi, Y. 1115, 1412
Auer, R. N. 129
Auwerx, J. 1528
Avery, N. C. 1131
Awata, T. 373

B

Bagdade, J. D. 487
Baggio, B. 1569
Bähr, M. 766
Bailey, A. J. 946, 1131
Bailey, S. R. 1345
Bain, S. C. 1108
Bak, J. F. 226
Baker, L. 915
Bakillah, A. 641
Balletshofer, B. 1540
Bandai, A. 1276
Bang, L. E. 1584, 1590
Bar-On, H. 1269
Barash, V. 1269
Barnes, D. 854
Barnett, A. H. 1108
Baron, A. D. 91
Barrow, B. 1325
Barthelow Classen, J. 500
Bartocci, L. 677
Bastide, R. 1498
Bataille, D. 135
Baum, H. 246
Baur, L. A. 621
Bazotte, R. 161
Bazzigaluppi, E. 1223
Beaty, B. 807
Beck-Nielsen, H. 142, 701, 1208
Becker, D. J. 3
Becker, H.-D. 462
Becker, W. 758, 1432
Bell, G. I. 725
Bellgrau, D. 28
Beltramo, E. 1263
Bena, E. 1263
Benazzi, E. 1223
Bendayan, M. 149
Bender, R. 77, 212, 368
Bendtsen, T. F. 1634
Benn, J. J. 976
Bennett, P. H. 433
Benz, S. 462
Berger, M. 77, 212, 749, 873
Bergholm, R. 1477
Berlini, C. 1413
Berne, C. 1539, 1603
Bertani, T. 1625
Berthezene, F. 701
Bianda, T. L. 961
Bicknell, J. 439
Bijlstra, P. J. 1083, 1562
Bilous, R. 1539
Bilous, R. W. 166, 1673
Birkeland, K. I. 1629
Bischof, F. 609
Björntorp, P. 206
Blair, A. 807
Blann, A. D. 868
Blombäck, M. 1519
Blum, M. 1036
Bock, M. 766
Bogardus, C. 314
Bognetti, E. 1409
Bolinder, J. 845
Bolli, G. B. 677
Bonet, B. 1041
Bonfanti, R. 1223
Bonifacio, E. 1223
Borboni, P. 289
Borg, K. 687
Boroujerdi, M. A. 976
Bortoluzzi, M.-N. 899
Bos, J. L. 558
Bosi, E. 1223
Bouchard, C. 1357, 1532
Boulton, A. J. M. 701, 1108
Bouter, L. M. 113, 298
Bouwens, L. 548
Bowes, S. B. 976
Bowsher, R. R. 831
Brandt, R. 1140
Brauers, A. 758
Bressler, P. 1345
Breteler, M. M. B. 1392
Brichard, S. M. 3
Brismar, K. 1519
Brocco, E. 1569
Brock, B. 1030
Bronson, M. 1489
Brösicke, H. 823
Brown, M. D. 103
Bruijn, J. A. 37
Brunetti, P. 677
Buchet, J. P. 3
Bugawan, T. L. 807
Buongiorno, A. 220
Burg, M. P. M. van der 37
Burkart, V. 119
Buschard, K. 658, 1329
Büsing, M. 462
Buyken, A. 929

C

Cabili, S. 1036
Caiola, S. 220
Caixàs, A. 1469
Calvert, G. D. 621
Cameron, N. E. 172, 1047
Campbell, D. R. 344
Campbell, L. V. 621
Canavan, J. P. 166
Capani, F. 1425
Caprio, S. 1489
Cardia, L. 1239
Carlberg, C. 1091
Carreras, G. 1469
Carson, D. J. 1063
Casanova, B. 22
Casini, A. 1055
Casla, A. 22
Caumo, A. 997
Cavallo Perin, P. 1372
Cavalot, F. 1156
Cerasi, E. 503, 1338
Ceriello, A. 469, 1003, 1405
Chaillous, L. 523
Chalé, J. J. 1498
Chambers, J. 854
Chan, C. B. 190
Chatellier, G. 1662
Chen, J.-W. 1590
Chen, X. 725
Chernihovsky, T. 1036
Chiumello, G. 1223, 1409
Chowdhury, T. A. 1108
Christensen, C. 1534
Christiansen, J. S. 961
Christie, A. W. 45
Christie, M. 1351
Cimminiello, C. 1402
Ciofetta, M. 677
Cipollina, M. R. 717
Cirulli, V. 474
Classen, D. C. 500
Clément, K. 82
Clements, R. S. 270
Cobelli, C. 997
Cohen, J. A. 270
Cohen, M. P. 270
Cohen, S. 537
Collins, P. 667
Cominacini, L. 364, 869, 1244
Concannon, P. 725
Consoli, A. 1425
Conti, M. 103
Cooney, G. J. 621
Corder, C. 492
Cormont, M. 899
Cosso, L. 1440
Cotter, M. A. 172, 1047
Courten, M. P. de 433
Cox, N. J. 725
Crepaldi, G. 1569
Cresci, B. 775
Creutzfeldt, W. 1546
Crosby, I. 1318
Cunningham, K. M. 481
Cusin, I. 353
Czyżyk, A. 831

D

D'Adamo, M. 220
Dahl, B. 1540
Dahlquist, G. 502
Dähne, R. 77
D'Alfonso, R. 289
Damert, A. 1165
Damm, P. 1329
Damsgaard, E. M. 1598
Daniels, T. 1091
Darquy, S. 523
Dauzats, M. 921
Davies, S. J. 1108
Davis, P. F. 1215
Davis, S. N. 103
Dean, J. D. 1108
Deerochanawong, C. 1070
DeFronzo, R. A. 1345
Deguchi, H. 1455
Del Sindaco, P. 677
Dell'anna, D. 952
Denoroy, L. 135
Dent, M. T. 336
DeSilva, M. G. 1237
Dhanasekaran, P. 915
Dheen, S. T. 1249
Di Mario, U. 775
Di Mario, V. 1055
Di Vincenzo, A. 677
Dimitriadis, E. 667
Doi, Y. 97, 800
Donaghue, V. M. 344
Donati, M. B. 1425
Donoghue, S. 701
Doria, A. 594
Dorrestijn, J. 558
Dosch, M. 747
Doyle, P. 353
Dresel, S. 970
Dronsfield, M. J. 1108
Droy-Lefaix, M.-T. 1255

Author index

A

Aaen, K. 658
Abaterusso, C. 1569
Abe, H. 1276
Abildgård, N. 226
Achenbach, P. 1351
Ackefors, M. 1091
Adu, D. 1108
Agardh, C.-D. 1313
Agardh, D. 1313
Agardh, E. 1313
Ahrén, B. 383, 649, 1099
Alberti, K. G. M. M. 45, 103, 322, 813, 961, 1227
Altomare, E. 1239
Andersen, A. S. 281
Anderson, L. G. 129
Andrén, B. 1603
Andreasen, F. 226
Anfossi, G. 1156
Angelico, M. C. 940
Annibale, B. 677
Aperia, A. 199
Araki, E. 412, 600
Arend den, J. A. C. J. 1562
Armstrong, M. 322
Arner, P. 845, 857, 921
Arrieta, F. J. 22
Asahina, T. 1115
Ashcroft, F. M. 1233
Assad, N. 275
Atsumi, Y. 1115, 1412
Auer, R. N. 129
Auwerx, J. 1528
Avery, N. C. 1131
Awata, T. 373

B

Bagdade, J. D. 487
Baggio, B. 1569
Bähr, M. 766
Bailey, A. J. 946, 1131
Bailey, S. R. 1345
Bain, S. C. 1108
Bak, J. F. 226
Baker, L. 915
Bakillah, A. 641
Balletshofer, B. 1540
Bandai, A. 1276
Bang, L. E. 1584, 1590
Bar-On, H. 1269
Barash, V. 1269
Barnes, D. 854
Barnett, A. H. 1108
Baron, A. D. 91
Barrow, B. 1325
Barthelow Classen, J. 500
Bartocci, L. 677
Bastide, R. 1498
Bataille, D. 135
Baum, H. 246
Baur, L. A. 621
Bazotte, R. 161
Bazzigaluppi, E. 1223
Beaty, B. 807
Beck-Nielsen, H. 142, 701, 1208
Becker, D. J. 3
Becker, H.-D. 462
Becker, W. 758, 1432
Bell, G. I. 725
Bellgrau, D. 28
Beltramo, E. 1263
Bena, E. 1263
Benazzi, E. 1223
Bendayan, M. 149
Bender, R. 77, 212, 368
Bendtsen, T. F. 1634
Benn, J. J. 976
Bennett, P. H. 433
Benz, S. 462
Berger, M. 77, 212, 749, 873
Bergholm, R. 1477
Berlini, C. 1413
Berne, C. 1539, 1603
Bertani, T. 1625
Berthezene, F. 701
Bianda, T. L. 961
Bicknell, J. 439
Bijlstra, P. J. 1083, 1562
Bilous, R. 1539
Bilous, R. W. 166, 1673
Birkeland, K. I. 1629
Bischof, F. 609
Björntorp, P. 206
Blair, A. 807
Blann, A. D. 868
Blombäck, M. 1519
Blum, M. 1036
Bock, M. 766
Bogardus, C. 314
Bognetti, E. 1409
Bolinder, J. 845
Bolli, G. B. 677
Bonet, B. 1041
Bonfanti, R. 1223
Bonifacio, E. 1223
Borboni, P. 289
Borg, K. 687
Boroujerdi, M. A. 976
Bortoluzzi, M.-N. 899
Bos, J. L. 558
Bosi, E. 1223
Bouchard, C. 1357, 1532
Boulton, A. J. M. 701, 1108
Bouter, L. M. 113, 298
Bouwens, L. 548
Bowes, S. B. 976
Bowsher, R. R. 831
Brandt, R. 1140
Brauers, A. 758
Bressler, P. 1345
Breteler, M. M. B. 1392
Brichard, S. M. 3
Brismar, K. 1519
Brocco, E. 1569
Brock, B. 1030
Bronson, M. 1489
Brösicke, H. 823
Brown, M. D. 103
Bruijn, J. A. 37
Brunetti, P. 677
Buchet, J. P. 3
Bugawan, T. L. 807
Buongiorno, A. 220
Burg, M. P. M. van der 37
Burkart, V. 119
Buschard, K. 658, 1329
Büsing, M. 462
Buyken, A. 929

C

Cabili, S. 1036
Caiola, S. 220
Caixàs, A. 1469
Calvert, G. D. 621
Cameron, N. E. 172, 1047
Campbell, D. R. 344
Campbell, L. V. 621
Canavan, J. P. 166
Capani, F. 1425
Caprio, S. 1489
Cardia, L. 1239
Carlberg, C. 1091
Carreras, G. 1469
Carson, D. J. 1063
Casanova, B. 22
Casini, A. 1055
Casla, A. 22
Caumo, A. 997
Cavallo Perin, P. 1372
Cavalot, F. 1156
Cerasi, E. 503, 1338
Ceriello, A. 469, 1003, 1405
Chaillous, L. 523
Chalé, J. J. 1498
Chambers, J. 854
Chan, C. B. 190
Chatellier, G. 1662
Chen, J.-W. 1590
Chen, X. 725
Chernihovsky, T. 1036
Chiumello, G. 1223, 1409
Chowdhury, T. A. 1108
Christensen, C. 1534
Christiansen, J. S. 961
Christie, A. W. 45
Christie, M. 1351
Cimminiello, C. 1402
Ciofetta, M. 677
Cipollina, M. R. 717
Cirulli, V. 474
Classen, D. C. 500
Clément, K. 82
Clements, R. S. 270
Cobelli, C. 997
Cohen, J. A. 270
Cohen, M. P. 270
Cohen, S. 537
Collins, P. 667
Cominacini, L. 364, 869, 1244
Concannon, P. 725
Consoli, A. 1425
Conti, M. 103
Cooney, G. J. 621
Corder, C. 492
Cormont, M. 899
Cosso, L. 1440
Cotter, M. A. 172, 1047
Courten, M. P. de 433
Cox, N. J. 725
Crepaldi, G. 1569
Cresci, B. 775
Creutzfeldt, W. 1546
Crosby, I. 1318
Cunningham, K. M. 481
Cusin, I. 353
Czyżyk, A. 831

D

D'Adamo, M. 220
Dahl, B. 1540
Dahlquist, G. 502
Dähne, R. 77
D'Alfonso, R. 289
Damert, A. 1165
Damm, P. 1329
Damsgaard, E. M. 1598
Daniels, T. 1091
Darquy, S. 523
Dauzats, M. 921
Davies, S. J. 1108
Davis, P. F. 1215
Davis, S. N. 103
Dean, J. D. 1108
Deerochanawong, C. 1070
DeFronzo, R. A. 1345
Deguchi, H. 1455
Del Sindaco, P. 677
Dell'anna, D. 952
Denoroy, L. 135
Dent, M. T. 336
DeSilva, M. G. 1237
Dhanasekaran, P. 915
Dheen, S. T. 1249
Di Mario, U. 775
Di Mario, V. 1055
Di Vincenzo, A. 677
Dimitriadis, E. 667
Doi, Y. 97, 800
Donaghue, V. M. 344
Donati, M. B. 1425
Donoghue, S. 701
Doria, A. 594
Dorrestijn, J. 558
Dosch, M. 747
Doyle, P. 353
Dresel, S. 970
Dronsfield, M. J. 1108
Droy-Lefaix, M.-T. 1255

Duguid, W.P. 256
Dunbar, P.R. 1215
Duner, E. 717
Dunger, D.B. 1108
Dworschak, A. 212
Dyrberg, T. 1329

E

Earle, K.A. 854
Eaton, R.P. 439
Ebeling, P. 124
Ebskov, B. 1607
Ebskov, L. 1607
Eckel, J. 766
Egberg, N. 1519
Eguchi, Y. 530
Eisenbarth, G.S. 807
Eizirik, D.L. 875
Emmison, N. 45
Eng, S. 725
Epifano, L. 677
Epstein, M. 907
Eriksson, J.W. 235
Eriksson, K.-F. 573
Eriksson, U.J. 401, 1123
Erion, M.D. 1148
Erlich, H.A. 807
Estacio, R.O. 1646

F

Fagrell, B. 1519
Falorni, A. 1091, 1196
Fanelli, C. 677
Fasching, P. 1242
Fatah, K. 1519
Faust, A. 119
Federici, M. 289, 952
Feher, M.D. 861
Felix, I. 1365
Fernqvist-Forbes, E. 687
Ferrannini, E. 1
Ferrer, J. 447, 891
Fioretto, P. 1569
Fischer, S. 1577
Flodström, M. 875
Flyvbjerg, A. 166
Fonteles, M.C. 731
Ford, I. 336
Forster, H.G. 907
Foulis, A.K. 127
Fraser, R. 984
Fratta Pasini, A. 869, 1244
Fredman, P. 658
Fresu, P. 1413
Frigato, F. 1569
Frittitta, L. 1190
Froesch, E.R. 961
Froguel, Ph. 82
Frøland, A. 1598
Frölich, M. 37
Frystyk, J. 1534
Führer, D. 251
Fujii, Y. 632
Fujisawa, T. 349, 747, 1398, 1410, 1412
Fujishima, M. 97, 800
Fukuda, M. 349
Fukuzawa, M. 263
Fuller, J.H. 1372, 1377
Fusco, A. 289
Fussgaenger, R.D. 421

G

Gabazza, E.C. 1455
Gaillard, R. 580
Gall, M.-A. 1590
Gallati, H. 60
Galli, G. 775, 1055
Gambara, V. 1625
Garbin, U. 364, 869, 1244
Gaskill, S.P. 1201
Gaur, L.K. 1313
Gautier, N. 899
Gee, A. 1534
Genovese, S. 1223
Gerbitz, K.D. 248
Geuk Seo, H. 793
Giaccari, A. 220
Giacomello, R. 469
Giannini, S. 775
Gibson, S.P. 1108
Gillmer, M.D. 1325
Ginsberg-Fellner, F. 1365
Giugliano, D. 357
Giurini, J.M. 344
Gjedde, A. 1534
Glaser, B. 1338
Glatz, Y. 961
Glawe, D. 1351
Goetz, F.C. 1365
Gold, D.P. 28
Goldfine, I.D. 1190
González-Sastre, F. 1469
Goor, Y. 1036
Gooren, L.J.G. 1284
Gooszen, H.G. 37
Gosling, R.G. 870
Gothefors, L. 502
Gottlieb, A. 492
Gough, S.L.C. 1108
Granner, D.K. 123, 322
Grant, P.J. 1512
Grattagliano, I. 1239
Greenhill, N.S. 1215
Gregersen, S. 1030
Greig, F. 1365
Gries, F.A. 823, 929
Griffey, R.H. 439
Griffin, M. 667
Grigorova-Borsos, A.M. 641
Grimminger, F. 251
Grobbee, D.E. 1392
Groop, L. 1505
Grootenhuis, P.A. 298
Gruber, H.E. 1148
Guerre-Millo, M. 1528
Gugliucci, A. 149
Guicherit, O.R. 37
Guillot, R. 641
Gumà, A. 1180
Gwodzinski, A. 462

H

Hadden, D.R. 1063
Haffner, S.M. 1201
Hahn, A.W. 1156
Hales, C.N. 1338
Halstrøm, J. 281
Hamada, Y. 349, 747, 1398
Hamman, R.F. 807
Hammersley, M.S. 1325
Hammes, H.-P. 251
Hamon, G. 166
Hanafusa, T. 126, 530
Hanaire-Broutin, H. 1498
Handberg, A. 142, 306, 1208
Hanefeld, M. 1577
Hanis, C.L. 725
Hanschke, R. 1140
Hansen, T. 1524
Hanson, R.L. 433, 1334
Hanssen, K.F. 1629
Harris, N. 329
Harskamp, F. van 1392
Hartmann, K. 1140
Hasan, Q. 1215
Hashimoto, N. 123
Haslbeck, M. 970
Hasselager, E. 281
Hattersley, A.T. 1325
Havelund, S. 281
Hawa, M. 60
Hayashi, T. 515
Hayek, A. 474
He, L. 1180
Hehmke, B. 1140
Heine, R.J. 113, 298
Heinrich, P.C. 1432
Heitkamp, G. 929
Hellström, L. 921
Hennessy, T.R. 976
Henquin, J.-C. 3
Henriksen, J.E. 1208
Herberg, L. 758
Hermansen, K. 1030
Herrera, E. 1041
Hershkop, K. 1269
Hessel, B. 1519
Higuchi, S. 1115
Hoffman, M. 807
Hoffmann, W. 1611
Hoffstedt, J. 838
Hofman, A. 1392
Hofmann, S. 248
Hohman, T.C. 172, 907
Holle, R. 1540
Holloway, D.L. 831
Holman, R.R. 1325
Holmäng, A. 206
Holness, M.J. 12
Holst, J.J. 1227, 1546
Holtey, M. von 766
Hopkins, K.D. 870
Hopmeier, P. 1611
Hoppe, E. 142
Hopt, U.T. 462
Hörmann, A. 1540
Horn, F. 1432
Horn, T. 658
Horowitz, M. 481, 984
Horton, V. 1233
Hosokawa, K. 1115
Huang, L.C. 731
Hughes, A.D. 861
Huppertz, C. 1432
Hussain, M.A. 961
Hussain, M.J. 60
Hypertension in Diabetes Study Group 1554

I

Iacoviello, L. 1425
Iaina, A. 1036
Ichikawa, F. 1306
Ichikawa, K. 97, 800
Idezuki, Y. 1276
Igel, M. 758
Iino, K. 97, 800
Ikegami, H. 245, 349, 747, 1293, 1398, 1410, 1412
Ilonen, J. 123
Imagawa, A. 126
Imperatore, G. 70
Inaba, T. 1276
Inada, C. 1306
Inoue, G. 515
Ionescu-Tirgoviste, C. 1377
Iovine, C. 70
Iovino, V. 70
Iozzo, P. 220
Isami, S. 412, 600
Itakura, M. 1462
Itoh, N. 126, 530
Iwahana, H. 1462
Iwahashi, H. 530
Iwase, M. 97, 800
Izumida, T. 373

J

Jackson, N.C. 976
Jäger, B. 1140
Jaksch, M. 248
Jakubowski, J.J. 329
James, M.A. 1385
Jansen, J.B.M.J. 37
Jéquier, E. 580
Jeanrenaud, B. 353
Jedynasty, K. 831
Jeffers, B. 1646
Jehle, P.M. 421
Jenkins, A.B. 618, 621
Jennische, E. 206
Jinayon, P. 1070
Johansson, B.-L. 199, 687
Johnson, A. 667
Johnsson, H. 1519
Jonassen, I. 281
Jones, D.B. 1318
Jones, K.L. 481
Joost, H.-G. 758, 1432
Jörneskog, G. 1519
Josefsberg, Z. 1338
Josefsen, K. 658
Joyce, J. 915

Juji, T. 371
Julius, U. 1577
Jun, H.-S. 1237

K

Kadowaki, T. 375
Kahn, C.R. 183, 600
Kahri, J. 453
Kainulainen, H. 758
Kaku, K. 800
Kalman, R. 1269
Kamp, G.J. van 1284
Kanatsuka, A. 123
Kaneko, K. 412
Karamanos, B. 929
Karlsen, A.E. 875
Karonen, S.-L. 993
Kasbohm, J. 1140
Kasperska-Czyżyk, T. 831
Kasuga, A. 1196
Katagiri, H. 447, 1196
Katayama, S. 373
Kawaguchi, R. 1115
Kawaguchi, Y. 1398, 1412
Kawai, K. 1241
Keller, A. 961
Kempler, P. 1372
Keymeulen, B. 54
Khatoon, A. 1108
Kibenge, M.T. 190
Kiehn, R. 766
Kikuchi, C. 373
Kiln, M.R. 248
Kimura, M. 1412
King, M.K. 439
Kishikawa, H. 412, 600
Klaff, L. 492
Kleemann, R. 1448
Klein, H.H. 249
Klingensmith, G. 807
Klip, A. 1180
Klischan, A. 929
Klöppel, G. 548
Knip, M. 123
Knowler, W.C. 314, 433, 1334, 1411, 1512
Kobayashi,Y. 1196
Köbberling, J. 873
Koefoed Theil, P. 1524
Koivisto, V.A. 124
Kolb, H. 119, 1448
Kolterman, O.G. 492
Kondo, M. 1410
Kono, S. 515
Koopmans, S.J. 391
Kosaka, K. 1196
Kostense, P.J. 113, 298
Kraemer, F.B. 45
Krämer, H.J. 251
Krans, H.M.J. 391
Krantz, S. 1140
Kriketos, A.D. 621
Křížová, J. 1074
Krolewski, A.S. 594, 940
Kucera, T. 161
Kühl, C. 1329
Kumar, S. 701, 1108
Kurtzhals, P. 281
Kuwajima, M. 126, 530
Kuwano, A. 447
Kuzuya, H. 515

L

La Selva, M. 1263
Ladrière, L. 990
Lahdenperä, S. 453
Lalli, C. 677
Lam, K.S.L. 368, 369
Lamers, C.B.H.W. 37
Lampasona, V. 747, 1223
Lampeter, E.F. 1351
Lan, M.S. 1001, 1237
Landau, H. 1338
Landgraf, R. 1415
Landin-Olsson, M. 1313
Landmesser, C. 1140
Lange, C. 1617
Langin, D. 921
Länne, T. 871
Lánská, V. 1074
LaPorte, R.E. 710, 1238
Larner, J. 731
Larsen, M. 1524
Larsen, U.D. 281
Larson, S. 1365
Larsson, H. 1099
Lauder, I.J. 369
Lauro, D. 952
Lauro, R. 289
Le Marchand-Brustel, Y. 899
Ledet, T. 696
Lee, J. 594
Lee, Y.-H. 1173
Lefèbvre, P. 1247
Lefèbvre, P.J. 580
Lehmann, E.D. 870
Leibiger, B. 1165
Leibiger, I.B. 1165
Leibowitz, G. 503, 1338
Leinsalu, M. 1238
Leiva, A. de 1469
Lemkes, H.H.P.J. 37
Leonetti, F. 220
Lepore, M. 677
Lernmark, Å. 1091, 1196, 1313
Leslie, R.D.G. 60
Lettis, S. 701
Levy, B. 492
Li, L.S. 857
Li, W. 537
Li, X.-B. 619
Lim, L.R. 725
Lind, L. 1603
Lindgärde, F. 573
Lindner, J. 1577
Lindsay, R.M. 1299
Lindsay, R.S. 1299
Lithell, H. 1603
Lithner, F. 1242
Liu, X. 537
Liu, Y.Y. 289, 952
Lo, S.S.S. 60
Lo, Y.-M.D. 1325
Lo Cascio, V. 364, 869, 1244
Locuratolo, N. 775
Loeken, M.R. 183
LoGerfo, F.W. 344
Lönnqvist, F. 838, 857
Lönnroth, P. 235, 613
Lorenzi, M. 735
Lorini, R. 370
Lowy, C. 976
Lund-Andersen, H. 1524
Luthman, H. 857
Lutterman, J.A. 1083, 1562
Lutz, M.P. 421

M

Maassen, J.A. 375, 558
MacDonald, F. 1108
Mackin, P. 1108
Maddux, B.A. 1190
Maggs, D. 615
Maioli, M. 1413
Majer, M. 314
Mäkimattila, S. 1477
Makino, H. 123
Makuuchi, M. 1276
Malaisse, W.J. 990
Malerczyk, V. 1617
Malik, R. 329
Mally, M.I. 474
Malmström, R. 993
Mandrup-Poulsen, T. 1005
Mansfield, M.W. 1512
Marinari, U.M. 1440
Marini, M.A. 289
Markussen, J. 281
Marotta, D. 1173
Marshall, S.M. 166, 1108
Martin, S. 747
Maruyama, M. 710
Massucco, P. 1156
Matsubara, A. 447
Matsuda, K. 600
Matsuda, M. 1345
Matsumoto, K. 412
Matsuoka, K. 1115, 1412
Matsushima, M. 710
Matsuura, N. 245, 371
Matsuzawa, Y. 126, 530
Mattiello, L. 1156
Mauer, M. 1569
Maugendre, S. 523
Mayer, H. 609
McCormack, L.J. 1512
McCormick, D.K.T. 45
McCullough, A. 1385
McDuffie, R.S. Jr. 807
McEvoy, R.C. 1365
McLellan, J.-A. 1325
McNally, P.G. 1385
Menè, P. 1055
Mengel, A. 813
Mennel, F.J. 609
Menzel, S. 725
Meschi, F. 1409
Metelko, Z. 1617
Metzger, B.E. 1126
Meyerhoff, C. 609
Micelli-Ferrari, T. 1239
Michaelis, D. 1140
Miettinen, H. 1201
Miki, T. 1398
Milani, M. 1402
Millns, H. 1233
Milne, R. 929
Mishra, M. 854
Miura, J. 245, 371
Miyagawa, J. 530
Miyamura, N. 412, 600
Miyazaki, J.-I. 1293
Miyazaki, J. 1462
Mizota, M. 245, 371
Mochizuki, H. 314
Modarelli, F. 677
Modi, W.S. 1001
Mody, C. 329
Mogensen, C.E. 1539, 1598, 1634, 1638
Mohamed-Ali, V. 1512
Mohri, M. 1455
Molinatti, G.M. 1263
Molinatti, P.A. 1263
Møller, J. 1227
Møller, N. 226, 813, 1227, 1534
Mølsted-Pedersen, L. 1329
Momiyama, Y. 1412
Monti, L.D. 103
Mooy, J.M. 298
Morgenthaler, N.G. 1351
Moriya, T. 632
Moriyama, S. 371
Morocutti, A. 854
Morris, P.J.M. 1108
Motoyoshi, S. 412, 600
Mott, D.M. 314
Motz, E. 469, 1405
Mrzljak, V. 1617
Muggeo, M. 701
Mühlhauser, I. 212
Muhr, D. 970
Mularoni, E.M. 1156
Mulder, H. 383, 649
Muollo, B. 1569
Muramatsu, T. 1115
Murase, T. 1196
Murata, C. 1115
Murata, K. 1455
Murphy, L.J. 1249
Muto, G. 263
Muto, Y. 263
Mutt, V. 135
Myrsén, U. 54

N

Nadeau, A. 1357
Nagi, D.K. 1512
Nagy, J. 1002
Nakagawa, Y. 245, 349, 747, 1241, 1398
Nakajima, H. 530
Nakanishi, K. 1196
Nakao, K. 515
Nakatani, K. 1455
Namba, M. 530

Nauck, M. A. 462, 1546
Neale, T. J. 1215
Nelson, R. G. 433
New, J. P. 166
Nielsen, F. S. 1584, 1590
Nielsen, S. 813
Nijpels, G. 113
Nishida, N. 793
Nishimura, R. 710
Nishioka, J. 1455
Noberasco, G. 1440
Noguchi, T. 530
Nolan, C. J. 785
Nonaka, K. 1306
Norazmi, M. N. 246
Norris, J. M. 807
Nosadini, R. 717, 1569
Notkins, A. L. 1001, 1237
Nowaczyk, R. 831
Nozawa, M. 1276
Nuber, A. 1377
Nyengaard, J. R. 1634
Nyholm, B. 813

O

Obel, J. 1584
Odegaard Wahlström, E. 1180
Odergren, T. 687
Odetti, P. 1440
Oga, T. 349
Ogihara, T. 245, 349, 747, 1293, 1398, 1410, 1412
Ohashi, S. 1241
Ohno, S. 632
Ohsuzu, F. 1412
Ohtomo, Y. 199
Oka, T. 1196, 1276
Oka, Y. 447
Okamoto, M. 515
Olds, R. J. 1325
Olsen, S. 1638
Omori, Y. 245, 371
Ordónmez-Llanos, J. 1469
Orho, M. 1505
Ørskov, C. 1227, 1546
Ørskov, H. 1534
Ørskov, L. 226, 1227
Osuga, J. 1276
Otani, T. 245
Otonkoski, T. 474
Ott, A. 1392
Ouwens, D. M. 558
Owens, D. 667
Oxlund, H. 946
Ozcelikay, A. T. 3

P

Paesano, P. L. 1409
Pagnozzi, F. 1263
Pali, T. 1255
Pampanelli, S. 677
Pan, D. A. 621
Pandolfi, A. 1425
Panerai, R. B. 1385
Paolisso, G. 357
Papavassilis, C. 251
Paquot, N. 580
Park, Y. H. 619
Parker, K. H. 1131
Parving, H.-H. 367, 1584, 1590
Passa, Ph. 82, 1662
Patterson, C. C. 1063
Payés, A. 1469
Payton, M. 1351
Pérez, A. 1469
Pérusse, L. 1357
Peakman, M. 60, 246
Pedersen, H. B. 1534
Pedersen, O. 314, 1524
Pedersen, O. B. 1584
Peer, G. 1036
Pelikánová, T. 1074
Permutt, M. A. 447, 891
Perry, G. 247
Persson, B. 701, 1091
Persson, H. 658
Petersen, J. S. 1329
Peterson, J. 492
Pettitt, D. J. 433, 1334
Pfeffer, F. 462
Pfeiffer, E. F. 609
Phillips, D. I. W. 1119
Piatti, P. M. 103
Pickkers, P. 861
Piddington, R. 915
Pietropaolo, M. 747
Pihl, M. 1483
Pikarsky, A. 1338
Pilkis, S. J. 1173
Piolot, R. 823
Pipeleers, D. G. 54
Pirastu, M. 1413
Pirisi, M. 469, 1003
Pittenger, G. L. 256
Plater, M. 1377
Plater, M. E. 336
Podar, T. 1238
Polderman, K. H. 1284
Polonsky, K. S. 564
Poncet, M. F. 1498
Popp-Snijders, C. 113, 298
Porta, M. 739, 1263
Posner, B. I. 235
Potter, J. F. 1385
Pour Mirza, A. 823
Pozza, G. 103, 1377
Prange, K. 212
Preston, F. E. 336
Pricci, F. 775, 1055
Printz, R. L. 123, 322
Prochazka, M. 314
Profozic, V. 1617
Proietto, J. 785
Pronzato, M. A. 1440
Pueyo, M. E. 82
Pugliese, F. 1055
Pugliese, G. 775, 1055
Pulido, N. 22
Purdy, L. P. 1126
Purrello, F. 244
Püschel, G. P. 161
Putiyanun, C. 1070

Q

Qualls, C. 439
Quinn, M. 940

R

Radder, J. K. 391
Rafaeloff, R. 256
Rahu, M. 1238
Raine, A. E. G. 1673
Rajkumar, K. 1249
Rakotoambinina, B. 82
Rambotti, A. M. 677
Rao, D. C. 1357
Rasmussen, L. M. 696, 946
Ravussin, E. 91
Reach, G. 523
Read, N. W. 481
Reichard, P. 1483
Reijonen, H. 123
Reinhardt, K. M. 868
Reinhardt, M. 823
Remahl, S. 687
Remuzzi, G. 1625
Rennie, I. G. 329
Reul, B. 3
Rewers, M. 807
Reynet, C. 183
Reynisdottir, S. 921
Ribel, U. 281
Riccardi, G. 70
Rice, T. 1357
Richter, E. A. 226
Rife, F. 1489
Rishaug, U. 1629
Ritter, M. 487
Rivellese, A. A. 70
Rivereau, A.-S. 523
Robert, J.-J. 82
Robertson, J. 1091
Rohner-Jeanrenaud, F. 353
Romanini, C. 952
Romano, G. 775, 1055
Romeo, G. 775, 1055
Rosenberg, L. 256
Rosenfeld, R. 1498
Rosenkranz, B. 1617
Rosenqvist, U. 1483
Rossing, P. 1590
Rosskamp, R. 1668
Rotella, C. M. 775, 1055
Rothe, H. 119, 1448
Rovira, A. 22
Rowe, B. R. 1108
Rowles, J. C. 314
Rowsell, P. 1448
Roy, S. 735
Rubinstein, P. 1365
Rüger, B. M. 1215
Russel, F. G. M. 1083, 1562
Russo, A. 984
Rydén Ahlgren, Å. 871

S

Sagara, M. 263
Sahlgren, B. 199
Sainsbury, A. 353
Saï, P. 523
Sakai, Y. 1410
Sakane, N. 1410
Saker, P. J. 1325
Sakura, H. 1233
Salazar, G. 135
Salkoff, L. 891
Sallerin-Caute, B. 1498
Sambataro, M. 1569
Sánchez-Quesada, J. L. 1469
Sarnow, M. R. 344
Sata, M. 1455
Satoh, J. 263
Sawicki, P. T. 77, 212
Sayre, L. M. 247
Sbraccia, P. 220
Schachter, M. 861
Schaden, W. 212
Schadewaldt, P. 823
Schäffer, L. 281
Scheen, A. 580
Scheen, A. J. 564
Scherbaum, W. A. 1351
Schernthaner, G. 1611
Schmechel, H. 1577
Schmitz, O. 226, 813, 961, 1227, 1534
Schnack, Ch. 1611
Schneiter, Ph. 580
Schnell, O. 970
Schommartz, B. 823
Schrier, R. W. 1646
Schulze, J. 1577
Schumacher, W. 929
Schwanebeck, U. 1577
Schwartz, C. 1432
Schwartz, S. 492
Scott, F. W. 619, 1448
Seckl, J. R. 1299
Seissler, J. 1351
Sellins, K. S. 28
Serirat, S. 1070
Sesti, G. 289, 952
Sever, P. S. 861
Shafrir, E. 1269
Shaver, A. 235
Shearman, C. W. 270
Sherwin, R. S. 1489
Shichiri, M. 412, 600
Shigemoto, M. 515
Shima, T. 1455
Shimada, F. 123
Shimizu, K. 710
Shimoda, S. 600
Shintani, M. 349, 1398
Shirotani, T. 412, 600
Sibbitt Jr, W. L. 439
Sillard, R. 135
Silverberg, D. 1036
Simell, O. 123
Sims, T. J. 946
Sips, H. C. M. 391
Sjöberg, S. 845
Sjöholm, Å. 243

Skjærbæk, C. 226, 1534
Skjærbæk, Ch. 813
Smidt, U.M. 1590
Smith, M.A. 247
Smith, P.R. 1108
Smith, U.P.G. 235
Smits, P. 865, 1083, 1562
Smrčková, I. 1074
Solntsev, A. 1238
Sönksen, P.H. 976
Spelleken, M. 766
Spielman, R.S. 725
Spinas, G.A. 701
Spraul, M. 91
Staehr, P. 1208
Staels, B. 1528
Stahl, R.A.K. 275
Standl, E. 970, 1540
Stehouwer, C.D.A. 1284
Steiner, G. 1655
Steiner, M. 868
Stel, L. 469
Stephens, E. 854
Stephenson, J.M. 1372, 1377
Stepień, K. 831
Stern, M.P. 1201
Sternberg, F. 609
Sternberg, M. 641
Stevens, L.K. 1377
Stewart-Long, P. 701
Stickland, M.H. 1512
Stiegler, H. 1540
Stolk, R.P. 1392
Storlien, L.H. 618, 621
Stradowska, I. 831
Stratton, I.M. 1505
Stříbrná, J. 1074
Stümpel, F. 161
Sturis, J. 564
Suárez, A. 22
Subbaiah, P.V. 487
Suga, J. 515
Sugden, M.C. 12
Sule, J. 1483
Sumida, Y. 1455
Sundkvist, G. 383
Sundler, F. 54, 383, 649
Suzuki, H. 1241
Suzuki, K. 1455
Suzuki, N. 401
Suzuki, Y. 1115, 1412
Svendsen, T.L. 1584, 1590
Svensson, K. 401
Swales, J.D. 1385
Syvänne, M. 453
Szymczak, W. 831

T

Taboga, C. 469
Taguchi, O. 1455
Tajima, N. 710
Takahashi, K. 263
Takahashi, T. 1410
Takane-Gyotoku, N. 1306
Takeda, J. 725
Takei, I. 1196
Takekawa, K. 349, 747
Takeya, H. 1455
Tally, M. 306
Tamborlane, W.V. 1489
Tamburrano, G. 220
Tanaka, K. 632
Tanaka, M. 1462
Taniguchi, N. 793
Taniyama, M. 1115
Tanizawa, Y. 447
Tappy, L. 580
Taskinen, M.-R. 453, 993
Tatsch, K. 970
Tauber, J.P. 1498
Tauber, M. 1498
Taylor, R.W. 322
ter Wee, P.M. 907
Tesfaye, S. 329, 1377
Thaiss, F. 275
The Microalbuminuria Captopril Study Group 587
Thien, T. 1083
Thien, Th. 1562
Thomas, N.M. 1365
Thomsen, J.L. 1030
Thörne, A. 838
Thuillier, F. 82
Thurston, H. 1385
Todaka, M. 412, 600
Todd, J.A. 1108
Toeller, M. 929
Tokunaga, K. 371
Tomita, K. 530
Tomkin, G.H. 667
Tomonari, A. 1462
Tonolo, G. 1413
Tonutti, L. 469
Tooke, J.E. 745
Tosaki, A. 1255
Toyota, T. 263
Traverso, N. 1440
Trevisan, M. 717
Trevisan, R. 717
Trischitta, V. 1190
Trovati, M. 1156
Tsujimoto, Y. 530
Tullio, A.N. 289
Tuomilehto, J. 1238
Tuominen, J.A. 124
Turnbull, D.M. 322
Turner, R. 1539
Turner, R.C. 1233, 1325, 1505

U

Uchigata, Y. 245, 371
Ueda, H. 349, 747, 1398
Ueda, K. 447
Uehara, M. 412
Umekawa, T. 1410
Umpleby, A.M. 976
Ura, S. 412, 600
Urios, P. 641
Utriainen, T. 1477

V

Vaaler, S. 1629
Vaccaro, O. 70
Vad, K. 281
Valensise, H. 952
Van Cauter, E. 564
Van den Berghe, G. 1148
Van den Berghe, N. 558
Van Obberghen, E. 899
Van Schaftingen, E. 1173
Vanelli, M. 370
Vargas-Rodriguez, I. 1365
Vargas Punti, M.D. 289
Vaxillaire, M. 82
Vedel, P. 1584
Veiga-da-Cunha, M. 1173
Velho, G. 82
Velussi, M. 1569
Vendemiale, G. 1239
Venkat Narayan, K.M. 1334
Verbruggen, I. 990
Vergani, D. 60, 246
Vestbo, E. 1598
Veves, A. 344
Viana, M. 1041
Viberti, G.C. 60, 854
Vicini, P. 997
Vigneri, R. 1190
Vincent, M.F. 1148
Vinik, A.I. 256
Vinten, J. 142, 1208
Virkamäki, A. 1477
Virsolvy-Vergine, A. 135
Vitacolonna, E. 1425
Vogt, L. 1140
Vosberg, H. 823
Vries, H. de 298

W

Wada, R. 263
Waddell, B.J. 1299
Wagner, O.F. 1242
Waguri, M. 126
Wahren, J. 199, 687
Wahrenberg, H. 838
Waldhäusl, W. 1242
Walker, M. 322
Wallach, E. 1365
Wallberg-Henriksson, H. 306, 1180
Wang, R.N. 548
Ward, J.D. 329, 336, 1377, 1676
Warram, J.H. 594, 940
Warren-Perry, M.G. 1505
Wasson, J. 891
Wat, N. 1233, 1505
Watanabe, Y. 1276
Watkins, P.J. 60
Webber, J. 1108
Weichenhain, B. 1540
Weintrob, N. 1338
Weiss, A. 251
Welsh, N. 875
Werner, J. 1546
Wesslau, C. 235
Weston, P.J. 1385
Willem, R. 990
Willms, B. 1546
Windeler, J. 873
Winlove, C.P. 1131
Wishart, J.M. 481
Wittmann, I. 1002
Wolf, G. 275
Wollman, Y. 1036
Wollschläger, D. 1546
Wongsuryrat, M. 1070
Worm, D. 142, 1208
Wörz-Pagenstert, U. 1448

X

Xie, H. 1001
Xu, L.Z. 1173

Y

Yagihashi, N. 793
Yagihashi, S. 263, 793
Yajima, Y. 632
Yamada, H. 245
Yamada, K. 515, 1306
Yamada, N. 1276
Yamagata, K. 725
Yamamoto, M. 97, 800
Yamashita, K. 1241
Yamato, E. 349, 747, 1293, 1398, 1410
Yanagisawa, K. 245
Yano, Y. 1455
Yanoff, M. 537
Ye, X. 537
Yeaman, S.J. 45
Yki-Järvinen, H. 993, 1477
Yoon, J.-W. 619, 1237
Yoshida, T. 1410
Yoshimasa, Y. 515
Yoshimoto, K. 1462
Yoshimura, R. 600
Yoshinari, M. 97, 800
Yoshioka, K. 1410
Yoshizumi, H. 97
Youngren, J. 1190
Yuan, X. 1306
Yudkin, J.S. 1407, 1512

Z

Zahner, G. 275
Zapf, J. 1534
Zhang, T.-M. 990
Zhang, Y. 1505
Ziegelasch, H.J. 1577
Ziegler, A.G. 970
Ziegler, D. 823
Zierath, J.R. 306, 1180
Zimmet, P. 1247
Zink, R. 462
Ziv, E. 1269
Zoja, A. 1409

Subject Index

KEY: A = Abstract in Supplement 1; b = Book review; c = Correspondence; r = Review or Debate; w = Workshop report

A

A-cell, pancreatic – glucotoxicity A 13
ABCD trial 1646
Acarbose 873 w, A 230
– clinical trial A 44
– haemostasis, effect on 469
– nutrient intake, effect on in diabetes A 195
– safety 1668 r
ACE *[see* Angiotensin – converting enzyme*]*
Acetyl-L-carnitine – diabetic neuropathy, use in A 261
– nerve, effect on in diabetic rat A 249
Acetylcholine – islet, effect on A 123
Acipimox *[see* Lipolysis – inhibitor*]*
Acromegaly – leptin in A 145
Actin – cytoskeleton – insulin, effect of – signalling A 55
Adhesion – kinase – focal – insulin receptor and A 170
– molecules – NIDDM, in – oxidised LDL, role of 1244 c
– – intercellular (ICAM) – 1 – islet B-cell, expression by A 101
– – – NIDDM 868 c, A 21
– – – diabetic macrovascular disease 1242 c
– – – expression – protein kinase C, role of A 282
– – – NOD mouse insulitis, role in A 98
– – serum – diabetes A 240
– – vascular cell (VCAM) – 1 – insulitis, role in A 97
– – – gestational diabetes A 205
Adipocyte – bradykinin receptor 412
– catecholamine sensitivity in relatives of obese subjects 921
– cell-line – 3T3-L1 – signalling pathways 1432
– GLUT4 A 171–A 173
– – Racb4, role of 899
– insulin resistance, glucose-induced A 12
– leptin expression 353
– – fat mass, effect of 758
– *ob* gene expression *[see OB* – gene*]*
– rat – acipimox, effect of 45
– tyrosine kinase – peroxovanadate, effect of 235
– vanadate, effect of 235
– visceral fat – insulin resistance syndrome 838
Adipose tissue – insulin,effect of A 177
– metabolism A 163
– microdialysis 845
Adrenalectomy – *fa/fa* rat, effect in 190
Adrenoceptor – α_2 – islet B-cell A 122
– – mutation – insulin resistance and A 46
– β_3 – adipocyte – insulin resistance syndrome 838
– – polymorphism – insulin resistance syndrome A 72
– – – obesity effect 857, 1410 c, A 6
– – – Type 2 diabetes 349, 1505
Adrenomedullin secretion in hypoglycaemia A 219
AGE *[see* Glycation – advanced end-product*]*
Age – insulin secretion, effect on A 124
– islet B-cell function and A 126
– – glucose tolerance A 193
– – microalbuminuria A 302
Ageing – insulin secretion and – pulsatility 564
AICA (5-amino 4-imidazolecarboxamide)
– riboside – fructose-1,6-bisphosphatase, effect on 1148
Albert Renold Fellowship 1996 *EASD News Section 10/96* 44
Albumin – acylated insulin binding affinity – species differences A 224
Albuminuria – diabetes – Type 2 – family hypertension and 433
– endothelial function and – Type 2 diabetes 1590
Alcohol – dehydrogenase – L-carnitine, effect of A 236
– diabetic neuropathy and 1377
– energy production, effect on – Type 2 diabetes A 8
– hypoglycaemia induction – sucrose, effect of A 218
Aldose reductase – diabetic retinopathy and A 244
– inhibitor – capillary basement membrane, effect on 641
– – diabetic neuropathy, in 172, A 248, A 260
– – – autonomic A 256
– – HIT cell glucotoxicity, protection against A 129
– – macroangiopathy protection A 287
– – tolrestat 907
– – zopolrestat – diabetic neuropathy, in A 35
– polymorphism – diabetic nephropathy and A 60
Aldosterone – insulin receptor expression, effect on – promonocytes A 188
– secretion – cisapride, effect of in diabetes A 226
Alloxan – diabetogenicity – atropine, effect of 383
Alzheimer's disease – diabetes and 1242 c
– glycation and 247 c
Amino acid – infusion – intraportal *vs* peripheral A 48
– – protein synthesis, effect on – p70 S6 kinase A 55
– metabolism – insulin, effect of A 179
Amputation in diabetes A 261, A 262
– incidence A 3
– – trend 1982–1993 1607
Amylin – analogue – pramlintide – renal clearance in rat A 235
– – treatment – diabetes – Type 1 492
– deficiency – mouse A 181
– endogenous – kinetics – hepatic vein study A 48
– expression – streptozotocin-diabetic rat 649
– gene – regulation A 128
– glucotoxicity, role in A 13
– mutation – diabetes – Type 2 A 5
– pharmacokinetics – man A 182
– secretion – constitutive A 56
– – diabetes – Type 2 A 149
– serum – insulin sensitivity, inverse correlation with A 68
Amyloid – islet – polypeptide (IAPP) *[see* Amylin*]*
Angiotensin – converting enzyme (ACE) – activity – renal hyperfiltration, in A 297
– – complications of diabetes and 97
– – diabetic renal hypertrophy, role in? 166
– – glucose transport, effect on – muscle A 180
– – inhibitor – albumin excretion rate A 42
– – – albuminuria, effect on A 305, A 307, A 308
– – – captopril 587
– – – glucose metabolism, effect on A 37
– – – hypertension & diabetes, in 1554
– – – low-dose therapy 1662
– – – microalbuminuria, in 587, 1611
– – – renal hypertrophy, effect on 166
– – polymorphism – atherosclerosis and 696
– – – diabetes complications A 60, A 61
– – – diabetic nephropathy 1108, A 296, A 297
– – – hypertension A 60
– – – Japan 97
– – – microalbuminuria A 74
– – – myocardial infarction and A 276
– II – degradation – glomerulus 275
Angiotensinase – A – glomerular expression – diabetic rat 275

Angiotensinogen – polymorphism – diabetic nephropathy 1108, A 60
Animal diabetes – International Workshop *EASD News Section 10/96* 54
Anorexia nervose – leptin in A 145
Anti-lipolytic drug *[see* Lipolysis – inhibitor*]*
Antibody – adrenal medullary – hypoglycaemia counterregulation, effect on A 218
– auto- – sympathetic ganglia – diabetes 970
– GAD A 86–A 93
– – 65 – diabetic retinopathy and A 244
– – – gestational diabetes 1329
– – diabetes – elderly A 191
– – – India A 81
– – – Type 1 – HLA and 1223
– – – Type 2 A 47
– – epitope specificity in Type 1 diabetes 1091
– – interferon α, induction by 126 c
– – mtDNA 3243 mutation and, in Type 1 diabetes 1196
– – prediction of Type 1 diabetes, in A 37, A 38
– – screening 1351
– glycated albumin – diabetic nephropathy, effect on 270
– IA-2 – assay – monoclonal IA-2 antibody displacament 1365
– – monoclonal 1365
– – screening 1351
– – Type 1 diabetes 1365, A 85, A 87
– – – prediction A 38
– islet-cell – 512 A 89
– – gestational diabetes A 18, A 204
– – glycolipid reactivity A 88
– – IA-2 – animal models of Type 1 diabetes 1237 c
– – – Type 1 diabetes – HLA 1223
– – intrauterine A 27
– – mtDNA 3243 mutation – Type 1 diabetes 1196
– – population studies A 46
– – prediction Type 1 diabetes A 38
– – surface A 89
– – time-resolved fluorescence imaging A 87
– – Type 2 diabetes A 76
– modified LDL A 270, A 280
– non-organ-specific – Type 1 diabetes A 93
– protein tyrosine phosphatase – IA-2 *[see* Antibody – IA-2 *]*
Anticoagulant system *[see* Haemostasis*]*
Antigen, islet-cell – 69kD – assay variation 747 c
– – tissue distribution 474
– GAD65 – viral sequence homology 1318
– IA-2 A 37, A 85
– – gene 1001 c
– protein tyrosine phosphatase *[see* – IA-2*]*
Antioxidant – free aminoacids A 225
– lipoic acid *[see* Lipoic acid*]*
– metallothionein – streptozotocin diabetes, effect on A 105
– serum total – Type 1 diabetes A 140
– status – prediabetes Type 1 A 94
– taurine *[see* Taurine*]*
– therapy – nerve, effect on in diabetic rat A 247
– – teratogenicity of diabetic serum, effect on A 208
Apolipoprotein *[see also* Lipoprotein*]* A 271
– B – diabetes A 65
– E – polymorphism – diabetic nephropathy A 299
– meal, effect of A 65
Apoptosis – enzyme expression – endothelial cell A 22
– Fas-mediated – islet 1306
– islet B-cell *[see also* B-cell, islet – cytotoxicity; Cytokine; Interleukin*]* A 107
– – *bcl-2* gene, protection by 530
– pericyte – hypoglycaemia-induced – glucose priming 537
Artery *[see also* Heart – coronary disease; Macrovascular disease*]*
– carotid – diabetes A 285, A 286
– – intima/media thickness by ultrasonography A 51
– cGMP production – streptozotocin-diabetic rat A 286
– compliance – diabetes, sex differences in 870 c
Ascorbic acid – antioxidant effect – diabetes A 141
Aspirin – low-dose – sulphonylurea interaction? A 221
– – peripheral vascular disease & diabetes 1402 r, 1405 r, 1407 r
Atherosclerosis – hyperinsulinaemia, role of 1276
Atrial natriuretic peptide – infusion – albumin excretion rate, effect on A 292
Atropine – alloxan diabetogenicity, effect on 383
Author index 1684
– EASD abstracts A 311
Autoimmune, Autoimmunity *[see also* Antibody, Antigen*]*
– gastric parietal-cell – diabetes and A 93
– islet A 27, A 28, A 85–A 89
– polyendocrinopathy – GAD65 autoimmunity A 85
– – Type 1 diabetes in A 93
– thyroid – Type 1 diabetes and A 93
– Type 1 diabetes – viral/GAD65 sequence homology and 1318

B

B-cell, islet *[see also* Glucotoxicity; Islet; Insulin – secreting cell; Insulin – secretion*]*
– apoptosis – *bcl-2* gene, protection by 530
– calcium ion fluxes A 116–A 119
– cytokine toxicity 1005 r
– cytotoxicity – Fas involvement 1306
– – glucose stimulation, effect of A 102
– differentiation A 63
– dysfunction – mechanisms A 126–A 130
– electrical activity A 116
– function in Type 1 diabetes A 92, A 96, A 126
– G-protein – interleukin-1β effect and 243 c
– gene expression, glucose-regulated 1293
– glucokinase 1173
– glucose sensing A 111–A 113, A 117
– glucose sensitivity – partial pancreatectomy ,effect of A 165
– growth & regeneration 548, A 64, A 108, A 109
– injury A 9, A 10
– – *bcl-2* gene, protection by 530
– ion flux A 49,A 50, A 115–A 120
– neurotransmitters, effect of A 122, A 123
– neurotropism 54
– nitric oxide synthase – regulation 875 r
– peptides, effects of A 71
– protein kinase C – δ – nuclear localisation A 169
– signal transduction A 111–A 120
– stimulus-secretion coupling A 39
– transfection – retroviral vector A 109
Bcl-2 gene – islet B-cell, protection of 530
Benzodiazepine – receptor – ligand – PK11195 – insulin secretion, effect on A 164
Beta-adrenergic blocking agent – (micro)albuminuria, effect on 1611, A 307
– celiprolol A 289
– hypertension & diabetes, in 1554
Biguanide *[see* Metformin*]*
Birth-weight, low *[see also* Nutrition – intrauterine; Pregnancy – nutrition*]*
– adult glucose metabolism, effect on 1299, A 53
– cardiovascular risk factors and – NIDDM 1598
– glomerular numbers, no effect on 1634
– Type 1 diabetes risk A 83
Blood – flow – diabetic foot A 4
– – forearm – diabetes – nitric oxide synthesis A 21
– – – sulphonylurea, effect of 1562
– – – Type 2 diabetes families 813
– – insulin, effect of A 152, A 175
– – islet A 110
– – nerve – diabetic rat 1047, A 246, A 247
– – – insulin neuritis 329
– – peripheral – pancreas transplantation, effect of A 132
– – skeletal muscle – diabetes – doxazosin, effect of A 226

– – skin – measurement A 216
– pressure *[see also* Hypertension*]* – ambulatory monitoring A 288, A 290
– – – diabetic children A 293
– – diabetic nephropathy, in – sodium intake and 212
– – diabetic retinopathy and A 243
– – glycaemic control, effect on A 295
– – hyperglycaemia, effect of – nitric oxide role A 239
– – islet capillary A 110
– – microalbuminuria, in A 301
– – toe – pulse oximetry A 286
Body fat *[see* Fat*]*
Bone – metabolism – diabetes A 309
– pancreas-kidney transplantation, effect of A 131
– mineral density – diabetes with microalbuminuria A 303
– – diabetic nephropathy and A 291
– – diabetic neuropathy and A 259
Bradykinin – adipocyte glucose uptake, effect on 412
– receptor 412
– – antagonist – streptozotocin diabetes, effect on A 98
Brain *[see also* Cognitive function*]* – Ca^{2+}, role of – diabetes A 163
– glucose utilisation – regional variation A 57
– natriuretic peptide – heart function and A 280
Breast-feeding *[see* Infant feeding*]*
BRLP-42 *[see* Hypoglycaemic agent*]* A 249

C

C-peptide – actions A 181
– binding – IM-9 lymphoblast 421
– endogenous – kinetics – hepatic vein study A 48
– glucose transport, effect on – mechanism 306
– insulin secretion, effect on A 71
– Na^+/K^+ ATPase, renal, effect on – neuropeptide Y synergy 199
– nerve function, effect on – autonomic 687
– selective loss from β-granules A 71
Calcitonin – diabetic neuropathy, use in A 261
Calcitriol – serum – diabetes A 211
Calcium – channel *[see also* B-cell, islet; Ionic flux; Islet*]*
– – blocking agent – albuminuria, effect on A 305
– – – dihydropyridine – nimodipine 129
– – – glucose metabolism, effect on A 36, A 37
– – – hypoglycaemic brain damage, in 129
– ionic flux – islet B-cell A 116–A 119
Calorimetry – indirect – muscle 103
Camillo Golgi lecture 1996 *EASD News Section 10/96* 44
cAMP (cyclic adenosine monophosphate) – smooth muscle 1156
Capillary – basement membrane *[see also* Glomerular – basement membrane*]*
– – diabetes – Type 1 A 43
– – glycation markers and 1140
– permeability – eye/kidney differences in diabetic rat A 305
– – diabetic retinopathy, in – ascorbic acid effect A 245
– – glucose, effect of – retina A 22
Carbenoxelone – pregnancy, effect in – rat 1299
Carcinoma – breast – insulin analogues and 124c
Cardiovascular risk factor A 274–A 279
– diabetes – Type 2 1577
– gender A 194
– gestational diabetes, in A 204
– insulin resistance A 68
– low birth weight and – NIDDM 1598
Carnitine *[see also* Acetyl-L-carnitine*]*
– palmitoyl transferase – islet B-cell A 39
Carotid *[see* Artery – carotid*]*
Castanospermine – insulin secretion, effect on A 112
Castelli Pedrosi prize 1996 *EASD News Section 10/96* 44
Catecholamine – glucose uptake, effect on A 186
– islet B-cell, effect on A 122, A 123
– lipolysis, effect on – relatives of obese subjects 921
– renal response to – Type 1 diabetes A 294
Cell – death, programmed *[see* Apoptosis*]*
– membrane – fluidity A 295
Cerebral *[see* Brain*]*
cGMP (cyclic guanosine monophosphate) – skeletal muscle A 162
– smooth muscle 1156
Charcot foot *[see also* Foot – diabetic*]* – prevalence A 262
Chiro-inositol glycan 731
Cholecystokinin – receptor – insulin-secreting cell A 124
Cholesteryl ester transfer – marine oil, effect of – diabetes 487
– protein A 269, A 270
Ciliary neurotrophic factor A 103
Clamp *[see also* Glucose; Insulin – resistance; Insulin – secretion*]*
– euglycaemic – GLP-1 (7–36 amide) study 1227
– – hyperinsulinaemic – glucokinase deficiency 82
– – – *Psammomys obesus* 1269
– – – muscle PTPase 1208
– – – pregnant rat 785
Clinical trial – ACE inhibitor in microalbuminuria – cardiovascular effects 1662
– Appropriate Blood pressure Control in Diabetes (ABCD) 1646
– design – Type 2 diabetes 1646–1667
– Diabetes Atherosclerosis Intervention Study (DAIS) 1655
Clonidine – transdermal A 289
Clotrimazole – islet B-cell, effect on A 122
Coagulation, anticoag'n *[see* Haemostasis; Endothelial; Fibrinolysis; Von Willebrand*]*
Coeliac disease – Type 1 diabetes and A 27, A 93
Coenzyme – Q10 (Ubikinon) – diabetes, use in A 227
Cognitive function – diabetes and 1392
– hypoglycaemia, effect of A 57, A 217, A 218
– intensive insulin therapy, after 1483
Collagen – arterial – ACE gene and 696
– glycation 1131, 1440
– – smooth muscle cell, effect on 800
– oxidation – glycaemic control and 1440
– type IV – endothelial cell, production by – glucose,effect of 641
– – retina – galactose-fed rat 735
– type VIII – mast cells, production by – diabetic nephropathy 1215
Complications of diabetes – ACE and 97
– avoidability A 202
– genetics A 60
– gestational diabetes, following A 18
– glycaemic control and 1483
– pancreas transplantation, effect of 1415r
– prevention A 202
– – antihypertensive therapy 1646
Contraceptive, oral – glucose metabolism A 188
Cow's milk *[see* Infant feeding*]*
CTLA-4 *[see* Lymphocyte – T – cytotoxic – associated protein 4*]*
Cushing's syndrome – glucose homeostasis – minimal model analysis A 188
– leptin in A 145
Cyclo-oxygenase – inducible – islet B-cell A 9
Cyclocreatine – insulin secretion, effect on A 31
Cyclosporin – nephrotoxicity – diabetes, in A 42
Cystic fibrosis – diabetes development A 83
Cytochrome – p450 – islet A 39
Cytokine *[see also* Interleukin; Tumour necrosis factor*]*
– 3T3-L1 cell, effect on – glucose transport 1432
– adipose tissue, production by A 238
– expression – pancreas – BB rat 1448
– interleukin – 1β – islet B-cell, effect on A 139
– islet-cell toxicity A 100–A 107
– – *bcl-2* gene, protection by 530
– – mediation 875r

Cytokine
– islet-cell toxicity
– – Fas involvement 1306
– macrophage-derived – Type 1 diabetes – twins 60
– Type 1 diabetes, role in A95
Cytoprotective enzymes – expression – insulin-secreting cell A10
Cytoskeleton *[see also* Adhesion – kinase*]* – insulin receptor and A170
Cytoskeleton – insulin, effect of A55

D

DAIS (Diabetes Atherosclerosis Intervention Study) 1655
DAISY (Diabetes Autoimmunity Study in the Young) 807
Dawn phenomenon A214
Deafness – diabetes with – maternally inherited 375r
Death *[see* Mortality*]*
– cell-, programmed *[see* Apoptosis*]*
Dehydroepiandrosterone sulphate, serum – diabetes care, role in? A211
Dementia – Alzheimer's disease – IDDM 1392
– diabetes and 1242c, 1392
Diabetes – care A28, A29, A198–A202
– – evidence-based 749r
– – – acarbose 873w
– – mortality and 710
– – primary *vs* central – hypertension control A287
– – psychological factors – foot ulceration, effect on A3
– congenital A97
– gestational A18, A203–A206
– – diagnostic criteria – WHO *vs* NDDG 1070
– – GAD antibody 1329
– – genetics – glucokinase mutation 1325
– – glucose metabolism 976
– – nephropathy following A306
– – prognosis for non-pregnant diabetes 1334
– latent autoimmune in adult (LADA) A47
– maturity onset in youth *[see* MODY*]*
– mitochondrial – subclinical cardiomyopathy 1412c
– Type 1 – aetiology A81
– – autoimmunity A15
– – childhood – incidence A190, A191
– – clustering A82
– – disease-modifying therapy *[see also* Nicotinamide*]*
– – – animal models A98–A100, A106
– – – insulin therapy A9, A52
– – environmental factors – nitrate in drinking water A16
– – genetic susceptiblity – neonatal HLA screening 807
– – heterogeneity A47, A62
– – immune response – viral/GAD65 sequence homology 1318
– – interleukin, role of 1005r
– – islet-cell antibody negative A92
– – slowly-progressive A90, A91
– Type 2 – complications – Symposium 1539–1678
– – Improving prognosis – preface to Symposium 1539
– – treatment – insulin *vs* sulphonylurea 1629
– – – sulphonylurea – cardiovascular dis. 503r
– – treatment *[see also* Diet; Exercise; Hypoglycaemic agent; Metformin; Sulphonylurea*]*
Dialysis – peritoneal – non-esterified fatty acids, serum A272
Diazoxide – K^+_{ATP} channel, effect on – gliclazide action 22
Diet A7, A8, A195–A198
– cholesterol A269
– diabetes – Type 1 – European survey 929
– fat – composition 621r
– – insulin sensitivity and 621r, A151
– – unsaturated – mono- *vs* poly- 667
– – – ω-3 487
– – high – glucose transport, effect on – skeletal muscle A174
– – – insulin resistance – rat A176
– – – insulin secretion, effect on A164
– – – leptin, effect on – mouse A146
– fish oil – lipoprotein subraction, effect on A271
– fructose – glucose production, effect on 580
– – insulin resistance induction in rat A172
– glucose – gastric emptying, effect on 481
– insulin resistance, effect on – laboratory rodents 618c
– protein – high – renal effect A305
– – pregnancy – offspring, effect on 12
– selenium – streptozotocin-diabetic rat 3
– sodium – diabetic nephropathy 212
– – insulin sensitivity, effect on A150
– vitamin *[see* Vitamin*]*
Differentiation – islet cell A108,A109
Digitalis-like substance – endogenous – diabetes A177, A238
Dopamine – renal production – diabetes A212
Drug – prescription – use by diabetics A195
Dynorphin – insulin secretion, regulation of A125
Dyslipidaemia *[see* Cholesterol; Hypercholesterolaemia; Hypertriglyceridaemia; Lipoprotein; Triglyceride*]*

E

EASD – General Assembly – Minutes, 1995 *(Suppl 1) I-V*
– Hon. Member – Dr Jean Pirart *EASD News Section 10/96* 48
– – Dr Samuel Rahbar *EASD News Section 10/96* 49
– Scientists Training Course 1997 *EASD News Section 10/96* 52
– Study Group – AIDSPIT *EASD News Section 9/96* 35w
– – diabetic nephropathy *EASD News Section 10/96* 50, 54
– – HID (Hypertension in Diabetes) *EASD News Section 8/96* 33
Ebselen – islet B-cell protection by A103
ECG, EKG *[see* Heart – ECG*]*
Editorial 1r
Education in diabetes A199–A202
– diet A197
– foot care A3
– hospital doctors A211
– pregnancy A207
Elastin – glycation 1131
Electrocardiogram *[see* Heart – ECG*]*
Eli Lilly/EASD Research Fellowship 1996 *EASD News Section 10/96* 44
Embryo / Fetus *[see also* Pregnancy*]*
– islet cell growth A109
– macrosomia – maternal obesity and A205
– maternal diabetes A206–A209
– neural crest cell migration – glucose,effect of 401
– prostaglandin E_2 – maternal diabetes, abnormal in 915
Embryopathy *[see also* Teratogenesis*]*
– diabetes A208, A209
– – neural tube malformation – mechanism 915
– – pregnancy – Vitamin E, effect of A19
Employment – diabetes, effect of A201, A202
Endorphin – β – hyperglycaemic effect in essential hypertension A290
Endosulfine 135
Endothelial, Endothelium – cell A21, A22
– – aldose reductase inhibitor, effect of 641
– – eicosanoids, effect of A174
– – glucose, effect of – thiamine, protection by 1263
– – – type IV collagen production 641
– – growth – insulin, effect of 206
– – hypoglycaemia, effect of – retina 537
– – kidney – growth factors A293
– – skeletal muscle – insulin, effect of 206
– D-glucose, effect of A139
– function – albuminuria and – Type 2 diabetes 1590
– – diabetes A239–A241

– – insulin sensitivity 1477
– – major artery – diabetes A281
– – microalbuminuria – Type 2 diabetes A303
– insulin, effect of – sex effect 1284
– protein kinase C – glucose, modulation by A168
– retina – microvascular remodelling, role in 739r, 746r
– vasoactive products – diabetic nephropathy, in A293
– – insulin, effect of 1284
– von Willebrand factor secretion – adrenaline-induced A67
Endothelin – 1 – expression – diabetic foot A267
– – hepatocyte, effect on 161
– – insulin secretion, stimulation of 1030
– – plasma – diabetic autonomic neuropathy, in A255
– – – microvascular angina, in A141
– carotid atherosclerosis and – diabetes A281
– retina – streptozotocin-diabetic rat A54
Energy – expenditure – glucose tolerance and A8
Environment – toxins – immunocyte, effect on – NOD mouse A84
Enzyme-to-enzyme channelling – Krebs cycle – insulin-secreting cell 990
Epidemiology – diabetes – dementia and 1392
– – Type 1 A190, A191
– – – Estonia – mortality 1238c
– – – Finland A82
– – – Lithuania A90
– – – Northern Ireland 1063
– – – Sardinians outside Sardinia A16
– – – social factors 1063
– – Type 2 A191–A194
– – – global epidemic 1247r
– diabetic neuropathy 1377
– diabetic retinopathy A242
– hypertension and impaired glucose tolerance 70
Epinephrine *[see* Catecholamine*]*
Erectile failure – assessment – Rigiscan A256
– vascular – treatment – embolisation A257
Erythromycin – gastric emptying, effect on A156
Ethanol *[see* Alcohol*]*
Europium fluorescence 142
Evidence-based medicine *[see* Diabetes – care – evidence-based*]*
Exercise – isometric – silent myocardial ischaemia testing A310
– – diabetes A189, A190
– – insulin resistance and – Type 2 diabetes families 813
– – prediabetes type 2 and 573
Exocytosis – islet B-cell – mechanism A40
Eye *[see* Cataract, Colour vision, Lens, Pupil, Retina, Retinopathy, Visual*]*
– choroid – pericyte – sulphatide 658
– redox status – diabetes 1239c

F

FAK *[see* Adhesion – kinase – focal*]*
Family study – diabetes – Type 1 – oxidative stress A294
– – – IA-2 antibody 1365
– – Type 2 A147–A149
– – – glucose metabolism phenotypes A46
– – – hyperdynamic circulation A36
– – – insulin resistance & exercise 813
– – – lens autofluorescence A245
– – – microalbuminuria & IGT A192
– – – paraoxanase polymorphism A64
– – – paternal *vs* maternal effects 831
– – – sib-pair ascertainment A73
– – – sympathoadrenal function A78
– diabetic nephropathy 940
– insulin resistance syndrome – Québec 1357
– MODY – insulin secretion & insulin sensitivity A73
– obesity – lipolysis – catecholamine resistance 921
– proteinuria and hypertension – Pima NIDDM 433
– twins – diabetes – Type 2 A15
Fas – islet, expression by – interleukin 1α, induction by 1306
Fat – *[see also* Adipocyte*]*
– distribution *[see also* Obesity*]* A150, A151
– – insulin resistance and – family study 1357
Fatty acid – essential – ascorbyl γ-linolenic acid 1047
– essential – diabetic neuropathy, effect on 172
– non-esterified – glucose production, effect on A49
– – glucose tolerance, effect on – acute 103
– – glucose uptake, effect on A48
– – insulin resistance syndrome, role in A53
– – insulin secretion, effect on A113, A114
– unsaturated – lipoprotein composition, effect on 667
– – ω-3 – cholesteryl ester transfer, effect on 487
– – – diabetic retinopathy 251
– – ω-6:ω-3 ratio 621r
Ferritin – diabetes A210
Fetus *[see* Embryo/Fetus*]*
Fibrinogen – cardiovascular risk factor – diabetes A274
Fibrinolysis – diabetes A238, A241
– – pregnancy A207
– hyperinsulinaemia, effect of A67, A279
– insulin, effect of 1425
– lipoprotein (a) phenotypes and – diabetes A237
– smooth muscle cell, effect of' 1425
Fibroblast – Na^+/H^+ antiport – Type 2 diabetes 717
Fibronectin – retina – galactose-fed rat 735
Fitness, physical *[see* Exercise – training*]*
Foot – diabetes A3, A4, A261–A268
Free radical – diabetic embryopathy, role in 1041
– insulin action and 357r, 364r
– scavenger – fetal cell migration, effect on 401
Fructose – 1,6-bisphosphatase 1148

G

G-protein – islet B-cell – interleukin-1β effect, role in? 243c
GABA (γ-amino butyric acid) – islet B-cell, release by A71
GAD *[see* Glutamic acid – decarboxylase; Antibody – GAD; Antigen – islet-cell*]*
Gall bladder – function – diabetes A256
Gastric emptying A156
– ^{13}C-octanoic acid breath test 823
– glucose, effect of 481
Gastritis – reactive – diabetes, in A309
Gene – expression – analysis – quantitative RT-PCR 747c
– – imaging – luciferase A40
– – ligation-mediated PCR 1293
– mitochondrial – depleted – endocrine cell line A76
– – diabetes 375r
– – IDDM – Japan 245c
– – mutant – 3243 – autoimmune Type 1 diabetes 1196
– – – diabetes – subclinical cardiomyopathy 1412c
– – – – Type 2 A6
– transcription – GG motif, role of – insulin gene 1462
– transfection – islet B-cell A128
Genetic screening – diabetes – Type 1 123c
Genetics – complications of diabetes A60
– diabetes – Type 1 A61, A62, A79–A81
– – – heterogeneity – age at onset 371c
– – – $IDDM_2$ – mapping 594
– – – mitochondrial gene 245c
– – – Na^+/H^+ antiport A73
– – – neonatal screening 807
– – Type 2 A5, A6, A72–A78
– – – β_3 adrenoceptor 349
– – – – obesity effect 1410c
– – – – gene 1505
– – – glucagon receptor gene 248c
– – – glucokinase mutation – founder effect 1325

Genetics
– diabetes – Type 2
– – – glycogen synthase 314
– – – insulin receptor substrate-1 gene 1505
– – – molecular scanning 600
– – – K^+ channels 447
– – – Kir6.2 polymorphism not associated 1233
– – – sex and 831
– – – trinucleotide repeats? 725
– diabetic nephropathy A296–A299
– – renin-angiotensin system 1108
– diabetic retinopathy – HLA 1313
– founder effect – glucokinase mutation and Type 2 diabetes 1325
– obesity 1528r, 1532r,
– polymorphism *[see* Polymorphism*]*
– trinucleotide repeats – Type 2 diabetes 725
Gerbil *[see Psammomys obesus]*
Gin and tonic hypoglycaemia A218
Gingko biloba – extract EGb 761 – myocardial ischaemia protection 1255
GIP – islet blood flow, effect on A110
– islet transplantation, following – dog 37
– receptor – mutant A182
– serum – dietary glucose, effect of 481
Glaxo Wellcome/EASD Burden of Diabetes Research Fellowship 47
Globin – glycation A137
Glomerular, Glomerulus
– advanced glycation end-products in 149
– afferent arteriole – galactose-fed rat 907
– angiotensinase A expression – diabetic rat 275
– basement membrane *[see also* Capillary – basement membrane*]* A304
– – freeze-etch study 632
– – insulin therapy, effect of 632
– extracellular matrix – Collagen VIII 1215
– – glucose, effect of 775, 1055
– filtration rate – measurement – iohexol A292
– macula densa – nitric oxide synthase expression 793
– mesangial cell – IGF system – glucose, effect of 775
– morphometry 793
– prostaglandin production – phospholipase source – diabetes A171
– stereology – low birth weight and 1634
– structure – microalbuminuria, in 1625
– – – Type 2 diabetes 1569, A294
GLP 1 A154–A156
– (7–36 amide) – glucose metabolism, effect on – skin A23
– – glycation, effect of A23
– – glycogen synthesis and – liver 1241c
– – insulin sensitivity, lack of effect on 1227
– – therapy – buccal tablet A43
– – – Type 2 diabetes 1546
– serum – dietary fat, effect of A196
Glucagon – fibrinogen synthesis, effect on A183
– glutamine uptake, stimulation of A183
– receptor – gene – Type 2 diabetes 248c
– – GLP-1 receptor comparison A154
– – mutation – insulin resistance and A74, A75
– – mutation – Type 2 diabetes A77
– secretion – amylin, effect of – GLP-1 comparison A154
– – Ca^{2+}, role of A118
Glucagonoma – protein metabolism, effect on A179
Glucocorticoid – fetus, effect on – adult glucose metabolism and 1299
– metabolic effects A187, A188
Glucokinase – hepatocyte A161
– islet – *fa/fa* rat 190
– islet B-cell – mutations 1173
– – structure & function 1173
– mutation – gestational diabetes 1325
– – insulin resistance 82
– – MODY, in 1413c, A73
– regulatory protein 1173
– transcription – cis *vs* trans – insulin-secreting cell A112
Gluconeogenesis – AICAriboside, inhibition by 1148
– fructose feeding, effect of 580
– liver – selenium, effect of 3
Glucose – 6 phosphatase – regulation – rat liver A13
– 6 phosphate – insulin resistance, role in – fat-fed rat A14
– disposal – hypoglycaemia, effect of 226
– – intracellular pathways in Type 1 diabetes A176
– futile cycling A158
– kinetics A157–A160
– metabolism – minimal model 997r
– monitoring – blind patient, by A216
– – continuous A215, A216
– production A48
– – fructose feeding, effect of 580
– – gluconeogenesis contribution – fasting man A160
– – pregnancy – rat 785
– sensing – islet B-cell A111–A113, A117
– sensor A215
– – subcutaneous – timing of response 609r, 613r, 615r
– tissue versus blood levels 609r, 613r, 615r
– tolerance – ageing and 564
– – assessment – comparison of different tests A159
– – impaired – cardiovascular risk factor A194
– – – hypertension and 70
– – – insulin resistance and insulin secretion 1099
– – – leptin in A144
– – – prediction 1201
– – – pregnancy – prognosis for diabetes 1334
– – – progression to diabetes A211
– – pregnancy – future diabetes risk 1334
– – test – IV – first-phase insulin response – childhood 370c
– – – – minimal model analysis 997r, A158, A159
– – – – – pregnancy 976
– – – – – familial aggreg'n A74
– – – – physical fitness and 573
– – – oral – reproducibility 298
– – – – prediabetes Type 2, in 113
– – – – pregnancy 1070, A203
– tracer A157, A158
– – 18F-fluorodexoyglucose – whole-body scintigraphy A220
– transport – 3T3-L1 cell – signalling pathways 1432
– – C-peptide, effect of – skeletal muscle 306
– transporter *[see* GLUT*]*
– turnover – methods A157–A160
– uptake – insulin-stimulated – RasGTP not involved 558
– – leptin, effect of – myotubes A59
– – measurement A215
– – skeletal muscle – sulphonylurea, effect of 22
Glucose-dependent insulinotropic polypeptide *[see* GIP*]*
Glucotoxicity *[see also* Insulin – secretion*]* A13–A14, A128, A129
– glucosamine, role of A14
– insulin-secreting cell A56
– transplanted islets A136
GLUT A171–A174
– 1 – polymorphism – hypertension association in diabetes A288
– – GLP-1 (7–36 amide), effect of – diabetic liver A155
– – insulin-secreting cell – sulphonylurea, effect of A30
– – islet – streptozotocin, effect of A106
– 4 – bradykinin, effect of – adipocyte 412
– – GLP-1, effect of – diabetic adipose tissue A154
– – pregnancy A208
– – skeletal muscle – hyperglycaemia, effect of 1180
– – translocation – Rab4, role of 899
Glutamic acid decarboxylase – 65 – viral sequence homology 1318, 246c
– antibody *[see* Antibody – GAD*]*
– cytokine expression, effect on A28
– molecular mimicry of *[see also* Antigen – islet-cell*]* 246c
– promoter, cloned A15
– serum A86

Glutathione – diabetic neuropathy, effect on 263
– oral – haemostasis, effect on in Type 2 diabetes A140
– platelet – Type 1 diabetes, in A295
Glycaemic control – assessment A201
– autonomic function, effect on A256
– blood pressure, effect on A295
– collagen damage, effect on 1440
– complications of diabetes and 1483, A34
– – neuropathy A35
– diabetes – Type 2 – immigrants A29
– LDL subfraction phenotype, effect on 1469, A273
– pramlintide, effect of in Type 1 diabetes 492
– stroke risk and A51
– target HbA_{1c} *EASD News Section 9/96* 38w
– Type 2 diabetes – evening blood glucose test A212
Glycation *[see also* HbA_{1c}*]*
– advanced end-product A137, A138
– – Alzheimer's disease 247c
– – cross-links 946, 1131
– – diabetic retinopathy, role in A54
– – dietary – diabetic nephropathy risk A70
– – endothelial cell – thiamine, effect of A21
– – glycaemic control – diabetic rat 1440
– – islet transplant, effect on A135
– – LDL, effect of 149
– – renal disposal 149
– – renal hyperfiltration and A301
– – serum – smoking, effect of A291
– – thiamine, inhibition by 1263
– – tissue damage, role in A22, A23
– – vascular stiffening, role in 946, 1131
– albumin – diabetic nephropathy, role in – *db/db* mouse 270
– clinical aspects A70
– collagen – smooth muscle cell, effect on 800
– fructosyllysine – receptor expression – macrophage 1140
Glycogen – phosphorylase – expression – diabetic rat muscle 183
– synthase – glucosamine, effect of A14
– – hypoglycaemia, effect of 226
– – mutation – insulin resistance and A45
– – polymorphism – Type 2 diabetes 1505, A6
– – – – Pima 314
– – protein phosphatase, effect of – PP2C – liver A160
– synthesis – GLP-1 (7–36 amide) and – liver 1241c
– – insulin-stimulated – RasGTP not involved 558
Glycolipid – sulphatide – pericyte – tissue distribution 658
Glycolysis – endothelial cell 1263
– islet – pyruvate channelling A39
Glycolytic enzyme – liver – selenium, effect of 3
GMP – cyclic *[see* cGMP*]*
Graves' disease – CTLA-4 gene and A79
Growth – cell – insulin receptor, role of A166
– factor – expression – islet A63, A64
– – insulin-like *[see* IGF*]*
– – mesangial – expression – age and A22
– – pancreas A108
– – pancreatic 256
– – platelet-derived – glucose transport, effect on 1432
– – – vitreous – diabetic retinopathy A26
– – transforming – β_1 – aminoguanidine, effect of A70
– – – foot ulcers, in A4
– – – mesangial 775, 1055, A43
– – – renal A293
– hormone – catabolic action – IGF-I, effect of 961
– – diurnal variation – diabetic retinopathy A244
– – insulin secretion, effect on – fetal islet A133
– – replacement – glucose metabolism, effect on A183
– – secretagogues – Type 2 diabetes, reduced effect in A184
– – secretion – pancreas transplantation, effect of A132
– islet A108, A109
– islet B-cell – streptozotocin-diabetic rat 548
GTPase – Rab4 – adipocyte – GLUT-4 translocation, role in 899
Gut *[see also* Gastric; Intestine*]* – motility – diabetes A310

H

Haemodynamic monitoring – diabetic nephropathy A295
Haemorrheology – diabetes A240, A241
Haemostasis; Anticoagulant system
– diabetes A237–A241
– – protein C activation 1455
– fibrin – gel structure – diabetes 1519
– pancreas-kidney transplantation, following A131
– postprandial activation – acarbose, effect of 469
– thrombomodulin, response to – diabetes 1455
Hamster – Syrian golden – streptozotocin-diabetic 256
Hazelnut – diabetes diet, in A197
HbA_{1c} – assay A213
– diabetes, Type 2 – mortality and 1540
– diabetic retinopathy progression and A242
Heart – adrenaline, effect of – diabetic dog A187
– arrhythmia – sulphonylurea compounds, effects of A235
– cardiomyocyte – troglitazone, effect of 766
– cardiomyopathy – ^{123}I-BMIPP scintigraphy 1412c
– coronary disease – diabetes A284, A285
– – insulin resistance and 1345
– – lipoprotein (a) and A272
– – Mauritius A68
– – microalbuminuria and – diabetes 854
– – prevalence – Type 2 diabetes A276
– – protection – sulphonylurea, effect of 1083
– – silent ischaemia 854, A284
– diastolic function – diabetes A251, A255
– ECG – dobutamine stress A284
– – hypoglycaemia, effect of A217
– – left ventricular hypertrophy – diabetes A279
– – non-esterified fatty acids, effect of A65
– – power spectral analysis 1385, A250, A251
– – QTc prolongation – diabetes A251–A253
– – – mortality in diabetic nephropathy 77
– – time domain analysis 1385, A250, A251
– innervation – diabetes 970
– inotropic agent – pimobendan A121
– ischaemic damage – diabetes, effect of 1255
– – *Gingko biloba* extract, protection by 1255
– K^+_{ATP} channel – sulphonylurea, effect of 503r
– left ventricular function – diabetes – isometric exercise testing A310
– – insulin-glucose infusion, effect of A279
– – Type 2 diabetes 1603
– left ventricular mass index – baroreceptor reflex sensitivity and 1385
– myocardial infarction – diabetes A283
– – diabetes – Type 2 1577
– – mortality – diabetes A51
– – prognosis – hyperglycaemia and A277, A278
– parasympathetic tone – hypoglycaemia, effect of A66
– preconditioning 1255
– sulphonylurea therapy, effect of 503r
– thallium scintigraphy A284
Heat shock protein – 65 – NOD mouse, effect on A98
Hepatic, Hepatocyte *[see* Liver*]*
Hepatitis – chronic active – interferon α therapy 126c

Herbal therapy – diabetes *[see* Hypoglycaemic agent – herbal*]*
Hexokinase – II – gene – mutant 322
– – regulation – pregnancy A209
– mitochondrial A129
– polymorphism – Japan 123c
HLA – Class I – Type 1 diabetes – age at onset 371c
– – expression A27
– Class II – Type 1 diabetes A79, A80
– – diabetic retinopathy, severe 1313
– diabetes, Type 1 – IA-2 antibodies 1223
– – mtDNA 3243 mutation 1196
– haplotype – diabetes – Type 1 A62
– neonatal screening – DAISY 807
– T-cell response, role in – viral antigen – Type 1 diabetes 1318
HMG CoA reductase inhibitor – lovastatin – diabetic nephropathy, in 367c
HOMA (Homeostasis model assessment) *[see* Insulin – resistance – HOMA; Insulin – sensitivity – homeostasis modelling*]*
Homocysteine – diabetes mortality and A282
– serum – Type 2 diabetes A228
Hyperglycaemia – intestinal motility, effect on 984
Hyperinsulinaemia – atherogenesis 1276
– gastric emptying, no effect on A156
– hypertension, with – prevalence A192
– insulin receptor, effect on – alternative splicing 220
– prediabetes – Type 2 – physical fitness 573
Hypertension *[see also* Blood – pressure*]* A287–A290
– low birth weight and 1598
– diabetes and A36
– – aldose reductase polymorphism A60
– – HID Study Group *EASD News Section 8/96* 33
– family history – albuminuria and 433
– hyperinsulinaemia, with – prevalence A192
– impaired glucose tolerance and 70
– left ventricular function and – Type 2 diabetes 1603
– Na^+/H^+ antiport – Type 2 diabetes 717
– treatment – albumin excretion rate, effect on A305, A306–A308
– – diabetes 1554
– – – Type 2 1611
– – doxazosin – lipids, effect on – diabetic rat A274
– – – muscle blood flow, effect on A226
– – intensive – diabetes 1646
– – moxonidine – glucose uptake, effect on A162
– white coat – Type 2 diabetes A42
Hypertriglyceridaemia – acipimox, effect of – rat adipocytes 45
– renal function, effect on 1074
Hypoglycaemia A57, A58, A66, A217–A222
– awareness – glycaemic control and 677
– – human insulin and 248c
– brain damage – nimodipine, effect of 129
– counter-regulation 226
– diabetes – Type 1 – Italy A200
– diabetic autonomic neuropathy, effect of 1372
– glycogen synthase, effect on 226
– infancy – nesidioblastosis 1338
– insulin receptor, effect on – downregulation A11
– intensive insulin therapy 677, 1483
– lipolysis, stimulation of – β-adrenergic mechanism 845
– non-islet-cell tumour – free IGF, role of 1534c
– oral hypoglycaemic agent therapy, during A230
– prediction – glucose sensor – sc 609r, 613r, 615r
– reactive – GLP-1, role of A156
– retina, effect on – glucose priming 537
Hypoglycaemic agent *[see also* Insulin – secretagogue; Metformin; Sulphonylurea*]*
– 4-hydroxyisoleucine A234
– AICA riboside 1148
– α-glucosidase inhibitor – acarbose *[see* Acarbose*]*
– BRLP-42 – neuropathy, effect on A249
– BTS 67 5 82 A43, A44
– buccal – GLP-1 (7–36 amide) tablet A43
– herbal A236
– – *Momordica charantia* – intestinal glucose transport A171
– – *Stevia rebaudiana* A125
– – *Trigonella foenum graecum* A234
– insulin mediator – chiro-inositol glycan 731
– moxonidine A162
– oral – safety aspects 1668r
– – secondary failure – management A212
– pimobendan A121
– selenium 3
– therapy – hypoglycaemia during A230
– thiazolidinediones – troglitazone A69, A232–A234
– – – *Erratum* 1245c
– – – heart, effect on 766
– – – Type 2 diabetes 701
– vanadate A124, A177
– – adipocyte, effect on A163
– – GLUT-4 expression, effect on A171
Hypotension – postprandial A175
Hypoxia – diabetic neuropathy, role in 344

I

IAPP *[see* Amylin*]*
ICAM *[see* Adhesion – molecule – intercellular*]*
IDF *[see* International Diabetes Federation*]*
IGF A184, A185
– binding protein A184, A185
– – 1 – transgenic mouse 1249
– – renal endothelial cells A293
– free – non-islet-cell tumour hypoglycaemia, role in 1534c
– I – diabetic renal hypertrophy, role in 166
– – insulin secretion, effect on in IGFBP-1 transgenic mouse 1249
– – mesangial-cell – glucose, effect of 775
– – receptor – insulin receptor hybrid – gestational hypertension 952
– – retina, expression in – diabetes A54
– – therapy – catabolic effect of growth hormone, effect on 961
– II – mesangial-cell – glucose, effect of 775
– – renal hyperfiltration and A301
– system – insulin infusion, effect of – intraperitoneal 1498
– thymic A15
Imidazolamine – receptor – islet B-cell A121, A122
Imidazole – antimycotic – islet B-cell, effect on A122
Imidazoline – compound – insulin secretion, effect on A30, A186
– – RX871024 – islet hormone secretion, effect of A235
– receptor – modulator – moxonidine A162
Immunocytochemistry – protein A-gold 149
Immunoglobulin – IgG1κ – serum – Type 1 diabetes A94
Infant feeding – cow's milk – Type 1 diabetes risk A82
Information – overload 1r
Inositolphosphoglycan – liver – GLP-1 (7–36 amide), effect of A154
Instructions to Authors *January & July issues*
Insulin – action A11, A12, A175–A177
– – endothelial cell growth 206
– – glycogen phosphorylase expression 183
– – IDF Congress satellite 1997 *EASD News Section 10/96* 54
– – oxidative stress and 357r, 364r
– analogue – carcinogenesis? 124c
– – fast – ^{B28}Asp A24
– – – lispro A24, A217, A221–A224
– – slow – Lys^{B29}-tetradecanoyl des-(B30) 281
– – – NN304 A24, A224
– antibody *[see* Insulin – autoantibodies; Insulin – immunogenicity*]*

- assay – endogenous insulin antibody, effect of A 212
- – immunochemiluminescent A 87
- – immunoradiometric A 86
- autoantibodies – assay – radio-binding A 47
- – neonatal A 96
- devices – study group (AIDSPIT) *EASD News Section 9/96* 35 w
- first phase response *[see* Glucose – tolerance – test – IV*]*
- gene – I – intron – regulatory function in rat 1165
- – promoter – glucose responsiveness A 31, A 32
- – region – diabetes – Type 1 594
- – regulation 1165
- – transcription – GG motif, role of 1462
- glycation, effect of A 23
- immunogenicity – autoimmunity and A 94
- – Type 1 *vs* Type 2 diabetes A 91
- implant – *Psammomys obesus* 1269
- infusion – continuous A 214
- – device – implantable pump 1498
- – intraperitoneal – IGF system, effect on 1498
- – portal – gluconeogenic efficiency A 157
- – pulsatile 391
- – subcutaneous – haemostasis & fibrinolysis, effect on A 238, A 241
- injection, sc – timing before meal A 52
- intranasal A 25
- islet B-cell injury, protection against A 9
- isophane – resuspension before injection A 212
- leptin synthesis. effect on A 59
- like growth factor *[see* IGF*]*
- neuritis *[see* Neuropathy – diabetic – painful*]*
- promoter factor – IPF-1 A 108
- receptor – binding – cross-linking A 165
- – bradykinin, effect of 412
- – C-peptide, no effect of 306
- – IGF-I hybrid – expression A 11
- – – gestational hypertension 952
- – insulinoma patients, in 220
- – internalisation – insulin resistance, in 289
- – isoforms – alternative splicing 220
- – – gestational hypertension 952
- – mutant – ^{973}Val/Met A 165
- – proinsulin receptor, distinct from – IM-9 lymphoblast 421
- – signalling A 166–A 171
- – – 3T3-L1 cell 1432
- – – IGF-1 receptor, different from A 11
- – – pH2.0 putative mediator 731
- – – phosphatidyl-inositol 3'-kinase, role of 515
- – – phosphotyrosine phosphatase 1208
- – – Ras-mediated 558
- – – regulation – PC-1 1190
- – substrate – 1 – gene – molecular scanning 600
- – – – – Type 2 diabetes 1505
- – – – insulin resistance, in A 6
- – – – mutation – Type 2 diabetes A 75
- – – – phosphatidyl-inositol 3'-kinase and 515
- – – – polymorphism – insulin signalling and A 77
- – – 66kDa protein A 166
- – tyrosine kinase – α_2-HS glycoprotein, effect of A 40
- – – inhibitor – PC-1 1190
- release *[see* Insulin – secretion*]*
- resistance – antihypertensive treatment, effect of A 36
- – cardiovascular risk factor A 68, A 277, A 278
- – childhood obesity 1489
- – chow-induced (laboratory rodents) 618 c
- – chronic renal failure, in A 296
- – coronary heart disease and 1345
- – diabetes, Type 2 A 149–A 153
- – – hypertension and A 36
- – diet, effect of – monounsaturated fat A 7
- – diet-induced – rat A 176
- – *fa/fa* rat – phosphotyrosine phosphatase 142
- – familial factors 1357
- – fat distribution and – family study 1357
- – fat-induced 621 r
- – glucokinase deficiency 82
- – glycogen synthase gene 314
- – hexokinase II mutant 322
- – HOMA 82
- – hyperinsulinaemia, in 220
- – hypertension, with – pregnancy 952
- – IDF Congress satellite *EASD News Section 10/96* 54
- – insulin receptor internalisation deficit in 289
- – insulin secretion and – glucose tolerance 1099, 1201
- – insulin signalling – adipose tissue A 166
- – intrauterine undernutrition, following 1119 r, 1123 r, 1127 r, A 53
- – liver – hexosamine pathway, role of A 14
- – macrovascular disease risk – oxidative stress, role of 1002 c
- – microalbuminuria and A 302
- – mixed hyperlipidaemia – diet, effect of A 7
- – phosphotyrosine phosphatase 1208
- – physical fitness and – Type 2 diabetes families 813
- – pregnancy A 207, A 208
- – *Psammomys obesus* 1269
- – relatives of Type 2 diabetic subjects A 147–A 149
- – syndrome A 45, A 46
- – – adipocyte β_3-adrenoceptor and 838
- – – β_3 adrenoceptor gene 349
- – – – obesity, confounding effect of 1410 c
- – – coronary heart disease as component 1345
- – – lipoprotein lipase mutation A 64
- – – non-esterified fatty acids, role of A 53
- – – plasminogen activator inhibitor gene 1512
- – troglitazone, effect of 701
- – – *Erratum* 1245 c
- secretagogue – cAMP phosphodiesterase inhibitor A 225
- secreting cell *[see also* B-cell, islet*]*
- – BRIN-D11 – glucose sensitivity A 117
- – Krebs cycle – enzyme-to-enzyme channelling 990
- – RINm5F – Krebs cycle 990
- – transfected – glucose sensors A 20
- secretion *[see also* B-cell, islet; Insulin – secreting cell*]* A 30, A 164, A 165
- – insulin resistance and – IGT prediction 1201
- – anion selectivity A 119
- – burst – sulphonylurea, effect of A 229
- – cytosolic Ca^{2+} and A 50
- – endothelin-1, stimulation by 1030
- – gestational diabetes A 18
- – $IDDM_2$ gene, effect of A 72
- – imaging – firefly luciferase chimaera A 32
- – insulin resistance, adaptation to 1099
- – measurement *in vivo* A 160
- – milrinone, effect of A 225
- – prediabetes – Type 2 – physical fitness 573
- – pregnancy – rat 785
- – pulsatility A 119, A 120
- – – ageing, effect of 564
- – – essential hypertension, in A 290
- – relatives of Type 2 diabetic subjects A 147–A 149
- – secretagogues A 121–A 125
- – stimulus-secretion coupling A 39
- sensitivity *[see also* Insulin – resistance*]*
- – antihypertensive drugs, effect of A 290
- – diet, effect of – high fat 621 r
- – endothelial function 1477
- – GLP-1 (7–36 amide), lack of effect of 1227
- – homeostasis modelling (HOMA) A 159
- – non-esterified fatty acids, effect of 103
- – oxygen free radicals, effect of A 140

Insulin-sensitivity
– – pulsatile insulin infusion, effect of 391
– species – hypoglycaemia awareness 248c
– specific – glucose tolerance test, in 298
– therapy A52
– – early – glomerular basement membrane, effect on 632
– – education A200, A202
– – intensive – adverse effects A52
– – – complications of diabetes, effect on 1483
– – – hypoglycaemia during A219
– – – long-term 677
– – metformin, combined A212
– – Type 2 diabetes 1629, A33, A34, A212
– – – glucose-modulated A180
– upstream factor *[see* Transcription – factor – IUF*]*
Insulitis *[see also* Lymphocyte*]* – cytokine expression – BB rat 1448
– immune effector molecules in 1005r
Interferon – α – islet, effect on A101
– – GAD antibody induction 126c
– γ – diabetes – Type 1 – twins 60
– – Type 1 diabetes, role in 1005r
– regulatory factor – insulin-secreting cell, in A102
Interleukin – 1 – polymorphism – Type 1 diabetes A79
– – – – twins 60
– – – diabetic nephropathy A298
– – signalling – islet B-cell 1005r, A9
– – Type 1 diabetes, role in 1005r
– 1α – islet cell toxicity – Fas involvement 1306
– 1β – islet B-cell, effect on 235
– – – apoptosis A10
– – islet, effect on – 2D gel electrophoresis A9
– – toxicity – islet A-to-B-cell differentiation, during A63
– 12 – islet, effect on A102
– 12 – NOD mouse 119
International Diabetes Fed'n – 16th Congress *EASD News Section 10/96* 57
Intestine – motility – hyperglycaemia, effect of 984, A156
Ionic flux – islet – endothelin-1, effect of 1030
Iron – insulin sensitivity, effect on A150
– metabolism – diabetes A210
Islet – amyloid – polypeptide *[see* Amylin*]*
– autoimmunity A85–A89
– B-cell *[see* B-cell, islet; Insulin – secreting cell; Insulin – secretion*]*
– capillary blood pressure A109
– cell – permeabilised – adenine nucleotide pools A112
– cryopreservation A134
– culture A133, A134
– differentiation A63
– function – IGFBP-1 overexpressing transgenic mouse 1249
– glycolysis – *fa/fa* rat 190
– growth A64, A108, A109
– interleukin 1α, effect of – Fas expression 1306
– innervation 54
– ionic flux – endothelin-1, effect of 1030
– K^+_{Ca} channel – cDNA 891
– muscarinic receptors A123
– regeneration – hamster 256
– Study Group – symposium report EASD News Section (3/96) 21

J

Janus kinase *[see* Kinase – Janus*]*

K

K^+ channel – inward rectifier – gene – islet 447
K^+_{ATP} channel – cardiovascular 1562
– diadenosine polyphosphates, effect of A115
– heart – sulphonylurea therapy, effect of 503r
– islet B-cell A121
– – cloned – properties A49
– – – Xenopus oocyte, expressed in A115
– Kir – BIR – mutational analysis A77
– Kir6.2 subunit – mutation – screening A74
– – polymorphism 1233
– sulphonylurea, effect of – rat skeletal muscle 22
– vascular – sulphonylurea, effect of 1083
K^+_{Ca} channel – islet – cDNA 891
– thiazide diabetogenesis, role in? 861r, 865r
Keratin – expression – duct-to-islet cell differentiation and A63
Ketoacidosis, diabetic – costs A200
– ventilatory response A310
Ketogenesis – growth-hormone-stimulated – IGF-I, effect of 961
Ketone body – kinetics – mathematical model A161
Kidney *[see* Glomerular; Microalbuminuria; Nephropathy; Renal; Transplantation*]*
Kinase – Janus – JAK/STAT pathway – glucose transport, effect on 1432
– MAP (mitogen-ativated protein-) – RasN17 mutant, effect of 558
– myosin light chain – insulin secretion, effect on A114
– p70 S6 – amino acid infusion, effect of – liver, muscle A55
– serin/threonine – adipocyte A12
Kinetics – measurements *in vivo* A157–A160
Krebs cycle – enzyme-to-enzyme channelling – insulin-secreting cell 990

L

Lactate – endothelial cell, productio by 1263
– insulin sensitivity, effect on A178
– intravenous – cerebral protection in hypoglycaemia A57
– metabolism – non-esterified fatty acids, effect of A178
LADA *[see* Diabetes – latent autoimmune of adults*]*
Lens – autofluorescence – Type 2 diabetes 1524
– – – relatives A245
– metabolism – streptozotocin-diabetic rat A54
Leptin A58, A142–A146
– adipocyte – neuropeptide Y, intracerebral, effect of 353
– expression – obesity, effect of – rodents 758
– – weaning – rat A7
– mRNA 353
– obesity, role in – insulin-induced A33
– plasma – insulin, effect of 993
– receptor – cloned – rat A146
Leucocyte – adherence – ischaemia, effect of A247
Lipase *[see also* Lipolysis*]*
– hormone-sensitive – acipimox, effect of 45
– inhibitor – insulin secretion, effect on A114
Lipids *[see* Apolipoprotein, Cholesterol, Hypercholesterolaemia, Hypertriglyceridaemia, Lipoprotein, Triglyceride*]* A64
Lipid-lowering therapy – fenofibrate 1655, A274
Lipogenesis – enzyme expression – diet, effect of A7
Lipoic acid – diabetic neuropathy, effect in A34, A261
– glucose uptake, effect on – signalling A11
– – Type 2 diabetes A226
– hypoglycaemic effect A139
Lipolysis – glucose, effect of A178
– growth-hormone-stimulated – IGF-I, effect of 961
– heredity, effect of 921
– hypoglycaemia – β-adrenergic mechanism 845
– inhibitor – acipimox – glucose tolerance, effect on 103
– – – rat adipocyte, effect on 45
– – monunsaturated fat 667
– – vanadate 235
Lipoprotein *[see also* Apolipoprotein, Cholesterol, Hypercholesterolaemia, Hypertriglyceridaemia, Triglyceride*]* A269–A274
– (a) – diabetes A65

– – fibrinolysis and – diabetes A 237
– – phenotype – albumin excretion rate and A 299
– HDL – composition – diabetes 667
– LDL – advanced glycation end-products, effect on 149
– – composition – diabetes 667
– – electronegative subform 1469
– – islet B-cell, effect on A 130
– – oxidised A 280
– – – adhesion molecules in Type 2 diabetes and 1244c
– – particle size – serum triglyceride and 453
– – subfraction phenotype – glycaemic control and 1469
– lipase – gene – diabetes – Type 2 1505
– – hyperinsulinaemia, effect of A 163
– – mutation – diabetes with obesity and hyperlipidaemia A 64
– oxidation – linoleic acid, protection by 667
– serum – pancreas transplantation, effect of A 132
Liver – chronic disease A 275
– diabetic autonomic neuropathy, effect of 161
– isolated perfused – hepatic nerve study 161
– metabolism A 160. A 161
Luciferase – gene expression imaging A 40
Lymphoblast – IM-9 – proinsulin binding 421
Lymphocyte – GAD65-reactive – homing receptor, gut-specific A 96
– T – cytotoxic – associated protein 4 – Graves' disease A 79
– – – – polymorphism & IDDM A 61, A 62
– – – – Type 1 diabetes A 79
– – helper – type 1/2 – NOD mouse 119
– – receptor – AV – repertoire in Type 1 diabetes A 95
– – subsets – prediabetes Type 1 A 95
– – superantigen, response to – BB rat 28
– – virus, response to – Type 1 diabetes 1318

M

Macrophage – cytokines – Type 1 diabetes 60
– fructosyllysine receptor 1140
Macrovascular disease *[see also* Artery; Heart – coronary disease; Vascular – disease*]*
– apolipoprotein A-IV and – Type 2 diabetes A 271
– chronic ambulatory peritoneal dialysis A 272
– clinical aspects A 51, A 283–A 287
– experimental A 67
– glycated collagen, role of 800
– intercellular adhesion molecules 1242c
– mortality – diabetes – Type 2 1540
– neuropathy, effect on 344
– pathogenesis A 279–A 283
– risk factors A 274–A 279
– vascular stiffening – glycation cross-links 946, 1131
Magnesium – diabetes A 210, A 225
Magnetic resonance – angiography – renal A 36
– imaging – brain – diabetes A 220
– spectroscopy – diabetic neuropathy 439
Malaria – hypoglycaemia during A 220
Malformation – fetal *[see* Embryopathy*]*
MAP kinase (mitogen-ativated protein kinase) *[see* Kinase*]*
Mass spectrometry – laser desorption/ionisation A 137
Mast cell – diabetic nephropathy, role in? 1215
Maternally-inherited diabetes with deafness 375r
MELAS (Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) 375r
– subclinical in mitochondrial diabetes – cardiomyopathy 1412c
Menstrual cycle – insulin requirement, effect on A 52
Mesangial cell *[see* Glomerular*]*
Metabolic regulation A 177–A 180
Metformin A 227, A 228
– insulin resistance, effect on – fructose-fed rat A 309
– insulin, combined therapy A 33
– phosphoenolpyruvate kinase, effect on A 160
– phosphotyrosine phosphatase, effect on – *fa/fa* rat muscle 142
– therapy – insulin, combined A 212
– – safety 1668r
Mexiletine – painful diabetic neuropathy, use in A 260
MHC – molecular mimicry – GAD 246c
MIBG (metaiodobenzylguanidine) – ^{123}I- – SPECT – heart 970
Microalbuminuria A 301–A 303
– cardiovascular risk factor 854
– – ACE inhibitor, effect of 1662
– diet, effect of – protein restriction A 196
– glomerular structure in – Type 2 diabetes 1569, 1625
– heart rate variability A 251
– hyperfiltration and – Type 2 diabetes 1584
– left ventricular hypertrophy and A 274
– Na^+/H^+ antiport – diabetes – Type 2 717
– prevalence A 191, A 192
– progression – ACE inhibitor, effect of 587, 1611
– – β-adrenergic blocking agent, effect of 1611
– – hypertriglyceridaemia and A 272
– renal hypertrophy and 1409c
– screening – diabetes A 291
– venous compliance, reduced A 67
Microangiopathy *[see also* Nephropathy, Nerve, Retinopathy*]*
– diabetic – ascorbic acid, effect of A 245
– – mechanism 641
– – risk factors A 26
– end-stage diabetic renal disease, role in 1673r
– epineurium – insulin neuritis 329
– monocyte fructosyllysine receptor expression and 1140
Microencapsulation – islet A 136
Microneurography – skeletal muscle sympathetic nerve 91
Minkowski Lecture – 1994 1005r
– 1996 *EASD News Section 10/96* 41
Mitochondria, Mitochondrial – Ca^{2+} – insulin secretion, role in A 117
– gene – diabetes 375r
– glycerophosphate dehydrogenase A 111
– respiratory chain activity – islet cells A 111
MODY (Maturity-onset diabetes in youth)
– family study – metabolic phenotype A 76
– glucokinase mutation 1173, A 73
– – insulin resistance study 82
– – Italy 1413c
Monocyte – advanced glycation end-product receptors A 138
– fructosyllysine receptor 1140
Morphometry – renal – microalbuminuria A 301
Mortality – blind people with diabetes A 245
– cardiovascular – microalbuminuria, in – ACE inhibitor trial 1662
– – Netherlands A 275
– – sulphonylurea therapy and 503r
– diabetes A 194
– – hypercholesterolaemia, effect of A 193
– – QTc interval A 253
– – Type 1 – childhood – Estonia 1238c
– – – risk factors – Japan 710
– – Type 2 1540
– – – risk factors 1577
– – young adults A 29
– diabetic foot problems A 4
– diabetic nephropathy – QT prolongation 77
– intensive insulin therapy A 52
– myocardial infarction – diabetes A 51
Mouse – alloxan diabetogenicity 383
– NOD – IA-2 antibodies not detected 1237c
– – insulitis A 98
– – – interleukin 12 119
– – porcine islet transplant 523

Mouse
– nude – islet transplantation 54
– partial pancreatectomy – insulin sensitivity A176
– transgenic – GLUT4/HKII A172
– – IGFBP-1 overexpressing – islet function 1249
Muscle – cardiac – culture 766
– skeletal – phosphotyrosine phosphatase – diabetes – Type 2 1208
– – blood flow – hyperglycaemia, effect of A45
– – – insulin resistance, role in A175
– – differential cDNA display – Type 2 diabetes A72
– – endothelial cell growth – insulin, effect of 206
– – fatigue – diabetes A17
– – glucose transport – C-peptide, effect of 306
– – glucose uptake – hyperglycaemia, effect of A45
– – GLUT4 A172–A174
– – – Type 2 diabetes 1180
– – glycogen phosphorylase expression 183
– – glycogen synthase – hypoglycaemia, effect of 226
– – indirect calorimetry 103
– – insulin sensitivity – PC-1 content and 1190
– – insulin signalling A166–A168
– – ketone body uptake – IGF-I, effect of 961
– – metabolism A162
– – – Type 2 diabetes families 813
– – microcirculation – pancreas transplantation, effect of A131
– – plasma membrane – glycoprotein 1190
– – protein metabolism – pancreas transplantation. effect of A179
– – sulphonylurea, effect of 22
– – sympathetic nerve activity 91
– – trinucleotide repeat expression – diabetes – Type 2 725, A78
– smooth – advanced glycation end-products, effect of A138
– – growth – GK Wistar rat A152
– – proliferation – glycated collagen, effect of 800
– – vascular – cAMP – insulin, effect of 1156
– – – eicosanoids, effect of A174
– – – fibrinolysis, effect on 1425
– – – oxidative stress A283
Myocardial infarction *[see* Heart – myocardial infarction*]*

N

N-acetylcysteine – diabetic neuropathy, effect on – rat 263
– fetal cell migration, effect on 401
N-deacetylase – expression – diabetic rat liver A309
Nephropathy – diabetic A42
– – aldose reductase – polymorphism A60
– – angiotensin converting enzyme and 97
– – angiotensinase A, glomerular 275
– – atherosclerosis in – homocysteine, role of? A282
– – clinical aspects A291–A296
– – collagen VIII in 1215
– – *db/db* mouse 270
– – diet – sodium restriction 212
– – EASD Study Group *EASD News Section 10/96* 50, 54
– – end-stage 1673r
– – genetics 940, A296–A299
– – – renin-angiotensin system 1108
– – glycated albumin antibody, effect of 270
– – lovastatin, effect of? 367c
– – mast cells, role of 1215
– – mortality – QT prolongation 77
– – natural history A306
– – neuropathy, role of A255
– – non-diabetic renal disease, distinction from 1638
– – protection – ACE inhibitor 587
– experimental A304, A305
– galactose-fed rat – aldose reductase inhibitor, effect of 907
Nerve – advanced glycation end-products A138
– antibody – sympathetic 970
– ascorbyl γ-linolenic acid, effect of – diabetic rat 1047
– blood flow – insulin neuritis, in 329
– – spectrophotometry A17
– endoneurial blood flow 172
– experimental studies A246–A249
– glucotoxicity – IGF-1, effect of A16
– GLUT – BB rat A172
– hydration 439
– regeneration – islet B-cell, effect of 54
– sympathetic – skeletal muscle – microneurography 91
Nesidioblastosis – proinsulin processing 1338
Neural crest cell migration – glucose, effect of 401
Neuropathy, diabetic A34, A257–A261
– aetiology A16
– ascorbyl γ-linolenic acid, effect of – rat 1047
– assessment 687, A17
– – Semmes-Weinstein monofilament A266
– autonomic A250–A256
– – autoimmunity? 970
– – baroreceptor reflex sensitivity 1385
– – C-peptide, effect of 687
– – cardiac 970
– – – assessment A17
– – exercise in A189
– – gastric emptying 823
– – gustatory sweating – treatment A35
– – haemodynamic effects of insulin A16
– – hepatic nerve function 161
– – hypertension in A36
– – hypoglycaemia awareness A58
– – hypoglycaemia risk 1372
– – mortality 77
– experimental A246–A249
– foot ulceration *[see* Foot*]*
– hypoxia, role of 344
– interacting mechanisms in 172
– magnetic resonance spectroscopy 439
– N-acetylcysteine, effect of – rat 263
– nerve hydration 439
– painful – mechanism 329
– prevalence 1377
– Type 2 diabetes 1676r
– von Willebrand factor and 336
Neuropeptide Y – insulin sensitivity, effect on A182
– intracerebral infusion – fat *ob* gene expression, effect on 353
– Na^+/K^+ ATPase, renal, effect on 199
– neurotropic effect 54
Neutrophil, polymorphonuclear – glycaemic control, effect of A310
Nicotinamide – diabetes development, effect on – mouse models A99
– diabetic nephropathy, no effect on in rat A304
– interleukin-1β cytotoxicity, effect on – insulin-secreting cell A106
– islet B-cell differentation, effect on A63
Nitric oxide *[see also* Endothelial – vasoactive substances*]*
– endothelial production – diabetes A239
– – insulin sensitivity 1477
– glucose uptake, effect on – skeletal muscle A168
– insulin secretion, role in A39, A113
– ischaemic renal failure, role in – diabetic rat 1037
– islet B-cell cytotoxicity, role in A100, A103–A106
– platelets – insulin, effect of A139
– synthase – inducible – BB rat insulitis 1448
– – inhibitor – diabetic neuropathy 172
– – – N-ω-nitro-L-arginine 1037
– – macula densa – streptozotocin-diabetic rat 793
– – myocardial – diabetes, effect of A21
– – regulation – islet B-cell 875r
Nitrosoamines – dietary – pregnancy – outcome A83, A206
Non-communicable diseases – global epidemic 1247r
Nutrition *[see also* Diet*]*
– intrauterine *[see also* Birth – weight – low*]*
– – adult glucose metabolism, effect on 12, 1119r, 1123r, 1127r, A49, A109
– – insulin sensitivity, effect on A176

O

Ob gene *[see also* Leptin*]*
– human – microsatellite polymorphism 1398
– mutant A 144
– product *[see* Adipocyte – leptin; Leptin*]*
Obesity *[see also* Leptin*]*
– abdominal – cardiovascular risk factor 838
– adipocyte lipolysis in non-obese relatives 921
– β_3 adrenoceptor polymorphism and 857, 1410c
– childhood – insulin resistance in 1489
– dexfenfluramine therapy A 225
– – pyruvate dehydrogenase A 152
– genetics 1528r, 1532r,
– hypoglycaemia counterregulation, effect on A 220
– leptin expression, effect on 758
– leptin, role of A 58
– maternal – fetal macrosomia risk A 205
– *OB* gene – microsatellite polymorphism 1398
– oxidative stress – diabetes risk factor A 141
– very low calorie diet A 195
Old age *[see* Age*]*
Oscillation – islet B-cell – ageing, effect of 564
– – cytosolic Ca^{2+} A 50, A 118, A 119
– – volume A 119
– somatostatin-producing cell A 118
Osteoarthropathy, diabetic *[see also* Foot – diabetic*]*
– fracture, role of A 263
Oxidative stress A 139–A 142
– atherosclerosis in insulin resistance, role in? 1002c
– diabetes – hypertension, effect of A 288
– diabetic retinopathy, role in A 243
– insulin action and 357r, 364r
– insulin-secreting cell, effect on A 105
Oxygen – free radicals – islet B-cell, effect on A 10

P

PACAP (Pituitary adenylate cyclase activating peptide)
– insulin-secreting cell and A 71
Pancreas, Pancreatic – bio-artificial A 133
– carcinoma – diabetes and A 70
– duct, partial obstruction of – islet regeneration 256
– growth factors 256
– polypeptide – islet transplantation, following – dog 37
– venous diversion – insulin resistance following A 180
Pancreatitis – tropical calcific – diabetes development A 81
Paraoxanase – polymorphism – Type 2 diabetes families A 64
Pedobarograph A 264
Pentosidine – advanced glycation end-product – collagen 1440
– – urinary A 137
Pericyte – sulphatide content – tissue distribution 658
Peroxynitrite – islet B-cell, effect on – human *vs* rat islets A 10
Phosphatidyl-inositol 3'-kinase A 167–A 170
– activation – rat hepatoma cell 515
– p85α A 12
– – dexamethasone-induced A 55
– – mutation – glucose tolerance A 5
Phosphofructokinase – deficiency – glucose metabolism, effect on A 153
Phosphotyrosine phosphatase in skeletal muscle – Type 2 diabetes 1208
– *fa/fa* rat 142
Pima Indians – plasminogen activator inhibitor polymorphism 1512
– Type 2 diabetes – glycogen synthase gene 314
Pituitary – infarction – antepartum A 206
Placenta – 11 β-hydroxysteroid dehydrogenase 1299
– GLUT1 – glucose, effect of A 173
Plasma – cell – antigen – 1 – gene mapping A 77
Plasminogen activator inhibitor – 1 – diabetes 1425
– – diabetes A 279, A 280
– – diabetic retinopathy A 26
– – gene – insulin resistance syndrome 1512
– diabetes A 238
– insulin resistance and A 152
Platelet – diabetes A 281
– – long-term insulin infusion, during A 238
– fish oil, effect of A 8
– insulin, effect of – nitric oxide role A 139
– protein kinase C A 55
Polycystic ovary syndrome – dexfenfluramine & diet therapy A 225
Polymerase chain reaction – ligation-mediated 1293
– reverse-transcriptase – quantitative 747c
Polymorphism – single-strand conformation 447
– single-stranded conformational 600
– – glucokinase 1325
– – Kir6.2 1233
Pramlintide *[see* Amylin – analogue*]*
Prediabetes *[see also* Prediction*]* – Type 1 A 94, A 95
– – control subjects for investigation 123c
– – cytokines – twin study 60
– – infections A 84
– Type 2 – parental diabetes – sex effects 831
– – proinsulin levels 113
Prediction – death – Type 2 diabetes at diagnosis 1577
– Type 1 diabetes A 37, A 38, A 89–A 95
– – GAD antibody 1091, 1351
– – genetic screening 123c
– – IA-2 antibody 1365
– – islet-cell antibodies – childhood A 15
– – neonatal screening – DAISY 807
– – tyrosine phosphatase antibody 1351
– Type 2 diabetes – gestational glucose tolerance 1334
– – glucose tolerance test 113
– – physical fitness, lack of 573
– – proinsulin 113
Pregnancy A 18
– diabetes A 206–A 209
– diet – vitamin E – streptozotocin-diabetic rat 1041
– glucocorticoid, placental transfer of – carbenoxolone effect 1299
– glucose metabolism 976
– – intrauterine protein nutrition and 12
– – rat 785
– glucose tolerance – criteria for GDM 1070
– – future diabetes risk 1334
– insulin resistance – hypertension and – insulin receptor 952
– nutrition during – metabolic effects on offspring 12, 1119r, 1123r, 1127r
– obesity A 205
Progesterone – islet cell growth, effect on A 64
– metabolic effects – rat adipocyte A 189
Proinsulin – assay A 214
– conversion – nesidioblastosis 1338
– convertase A 32
– – maturation A 164
– – PC2 – polymorphism in Type 2 diabetes A 78
– coronary heart disease A 277
– glucose tolerance test, in 298
– impaired glucose tolerance, in 113
– receptor – IM-9 lymphoblast 421
– secretion – relatives of Type 2 diabetic subjects A 148
– serum – Type 2 diabetes A 153, A 255
– – gestational diabetes A 19
– – prediabetes Type 1 A 94
Promoter – insulin – IPF-1 A 108
Prostacyclin *[see* Endothelial – vasoactive substances*]*
Prostaglandin – E_2 – embryo – diabetic mouse 915
– mesangial cell, synthesis by – glucose, effect of 1055
Protein – kinase – C A 168
– – – activation – platelets A 55
– – – cardiomyocyte 766

Protein – kinase – C
– – – isoenzymes – islet B-cell, specificity in A 114
– – cAMP-dependent – acipimox effect in rat adipocyte 45
– – mitogen-activated – insulin, activation by A 41
– – – skeletal muscle A 167
– phosphatase – serine/threonine – islet B-cell A 39
– uncoupling – polymorphism – insulin resistance syndrome A 72
Psammomys obesus – insulin resistance 1269
– leptin A 146
Psychology – well-being *[see also* Quality of life*]*
– – diabetes A 199
– – intensive insulin therapy 1483
Puberty – insulin resistance A 178
Pulsatility – insulin infusion 391
Pulse oximetry – toe arterial pressure A 286
Pyruvate – kinase – promoter – glucose activation – islet B-cell A 40

Q

Quality of life – diabetes A 198
– pancreas transplantation, effect of 1415 r

R

Ras – insulin signalling, role in 558
– – adipocyte A 170
– – islet B-cell 558
Rat – BB – cytokine expression in pancreas 1448
– – diabetes – GLUT-2 expression in islet B-cell A 106
– – IA-2 antibodies not detected 1237 c
– – progenitor – insulin resistance syndrome A 153
– – recovery from diabetes A 102
– – superantigen tolerance induction in 28
– BB/Pfd – autoimmune memory and A 97
– galactose-fed – renal autoregulation – aldose reductase and 907
– Goto-Kazikaki (GK) – cardiac hypertrophy A 67
– – genome scan A 5
– – insulin secretion, impaired A 45
– – – nitric oxide in A 56
– – islet studies A 126, A 127
– – pregnancy – fetal abnormalities A 206
– hereditary hypertriglyceridaemic – brown Norway hybrid A 75
– hindquarter perfusion – gliclazide, effect of 22
– intrauterine malnutrition, effect of – subsequent pregnancy 12
– Otsuka Long Evans Tokushima Fatty A 151
– – neuropathy A 248
– spontaneously hypertensive diabetic – BB. Sa A 289
– streptozotocin-diabetic – amylin expression 649
– – embryopathy – vitamin E, effect of 1041
– – glomerular basement membrane 632
– – glucose uptake, reduced A 180
– – hepatic nerve function 161
– – neonatal – islet B-cell growth 548
– – neuropathy 172
– – phosphoenolpyruvate kinase activity A 160
– – renal hypertrophy 166
– – retinopathy 251
– – selenium, effects of 3
– Zucker *fa/fa* – adrenalectomy, effect of 190
– – leptin receptor A 146
– – phosphotyrosine phosphatase 142
Referees list 1679
Regeneration – islet *[see* Growth – islet B-cell; Islet – regeneration*]*
Relatives *[see* Family study*]*
Renal – advanced glycation end-products A 23
– artery stenosis – Type 2 diabetes A 36
– biopsy – renal disease in diabetes 1638
– disease in diabetes – end-stage 1673 r
– – non-diabetic pathology 1638
– dopamine production – diabetes A 212
– failure – insulin sensitivity – low-protein, low-phosphate diet A 179
– – ischaemic – nitric oxide role – diabetic rat 1037
– glucose production – diabetes – Type 1 A 48
– haemodynamics – hypertriglyceridaemia, effect of 1074
– – insulin, effect of – Type 1 diabetes 1074
– – prospective study – Type 1 diabetes A 42
– – transplantation, following A 130
– hyperfiltration A 300, A 301
– – microalbuminuria, with – Type 2 diabetes 1584
– hypertrophy – mechanism 166
– – microalbuminuria and – diabetes 1409 c
– impairment – sulphonylurea use in – glimepiride 1617
– nitric oxide responsiveness – Type 2 diabetes A 239
– sodium handling – hypertriglyceridaemia, effect of 1074
– – insulin, effect of – Type 1 diabetes 1074
– tubule – advanced glycation end-products disposal, role in 149
– – function – Type 2 diabetes A 292
Renin – angiotensin system – complications of diabetes and A 288
– – streptozotocin-diabetic rat 793
– serum – diabetic retinopathy marker A 243
Research – diabetes – Europe *Organisation Section, September issue*
Respiratory function – diabetic ketoacidosis A 310
Retina – basement membrane – galactose-fed rat 735
– endothelial cell – function & proliferation in diabetes 1263
– microvascular remodelling – endothelium, role of 739 r, 746 r
– pericyte – hypoglycaemia-induced apoptosis 537
– pigment epithelial cell – myo-inositol transport A 169
Retinopathy – diabetic A 25, A 26, A 242–A 245
– – angiotensin converting enzyme and 97
– – endothelium, role of 739 r, 746 r
– – experimental A 54
– – fish oil, exacerbation by – rat 251
– – genetics – HLA 1313
– galactosaemic – basement membrane composition 735
Risk – stratification A 193
Ryanodine – receptor – islet B-cell A 50

S

Salivary gland – Type 1 diabetes A 95
Sand rat *[see Psammomys obesus]*
Science and patient care in diabetes 749 r
Scientists Training Course *EASD News Section 1/96; 10/96* 52
Screening – diabetes – hospital inpatients A 211
– – lens fluorimetry 1524
– – Type 1 A 46, A 89
– foot problems – diabetes A 3
– HLA – neonatal 807
– islet-cell antibodies *[see also* Prediction – Type 1 diabetes*]*
– microalbuminuria – diabetes A 291
Selenium *[see also* Hypoglycaemic agent*]*
Sialic acid – serum – cardiovascular risk factor A 275
Signal transduction A 40, A 166–A 171
– islet B-cell A 111–A 120
Signalling, intracellular A 55
Single-photon emission tomography – ^{123}I-MIBG – heart 970
– thallium – cardiovascular risk A 51
Single-stranded conformation polymorphism *[see* Polymorphism*]*
Skin – blood flow – measurement A 216
– keratinocyte culture graft – diabetic foot ulcer A 4
– structure – arm *vs* foot A 266

Smoking – advanced glycation end-products, serum A 291
– insulin resistance A 173
Socioeconomics – diabetes care and A 199
– Type 2 diabetes – global epidemic 1247 r
Sodium – blood pressure and – diabetic nephropathy, in 212
– exchangeable body 212
– insulin secretion. role in A 113
– transport – Na^+/H^+ – family study – Type 1 diabetes A 73
– – Type 2 diabetes 717
– – Na^+/K^+ ATPase – diabetic neuropathy and A 258
– – – renal – C-peptide, effect of 199
– – Na^+/Li^+ counterport – blood pressure and A 293
– – – cardiac function and A 283
– – – diabetes, in – prospective study A 306
Somatostatin – glucose metabolism, effect on A 182, A 183
– secretion – oscillation A 118
Sorbitol – dehydrogenase A 248
Specific insulin *[see* Insulin – specific*]*
SPECT *[see* Single-photon emission tomography*]*
St Vincent Declaration – pregnancy A 208
Stat protein (Signal Transducer and Activator of Transcription) *[see* Kinase*]*
Stature – short – gestational diabetes association A 203
Steroid *[see* Glucocorticoid*]*
Stevia rebaudiana – insulin secretion, effect on A 125
Stiff man syndrome A 27
Stockholm Diabetes Intervention Study 1483
Streptozotocin – diabetogenicity – maternal factors – nitrosoamines A 83
Stroke – insulin resistance A 277
Succinic acid – derivatives – insulin secretion, effect on A 125
Sulphatide *[see* Glycolipid*]*
Sulphonylurea A 229–A 232
– action – Kir6.2 polymorphism and 1233
– cardiovascular effects – K^+_{ATP} channel 1083
– compounds – cardiac arrhythmias, effect on A 235
– failure – insulin *vs* metformin therapy A 33
– gliclazide – skeletal muscle, effect on 22
– glimepiride 1083
– – renal impairment, use in 1617
– glipizide – modified-release A 231
– insulin secretion, effect on – first- *vs* second-phase A 44
– insulin, combined therapy A 33
– K^+_{ATP} channel, effect on – protein kinase C and A 30
– receptor *[see also* K^+_{ATP} channel*]*
– – endogenous ligand – endosulfine 135, A 235
– – mutation – islet B-cell, effect on A 56
– – polymorphism – insulin secretion and A 5
– – – obesity A 72
– skeletal muscle, effect on 22
– therapy – cardiovascular effect 503 r
– – insulin, combined A 212
– – safety 1668 r
– – secondary failure 1629
– vascular reactivity, effect on 1562
Superantigen – tolerance induction – BB rat, abnormal in 28
Superoxide dismutase – hyperglycaemia, effect of A 13
Sweating – gustatory – glycopyrrolate, effect of A 35
Sympathetic nerve – skeletal muscle – microneurography 91
Synaptotagmin – islet B-cell, localisation in A 115
Syndrome X, metabolic *[see* Insulin – resistance – syndrome*]* A 153
Syntaxin – insulin secretion, role in A 118

T

T-cell *[see* Lymphocyte – T*]*
TAP (Transporter associated with antigen processing)
– 2 – polymorphism – Type 1 diabetes A 80, A 81
Taurine – insulin secretion, effect on A 164
– transporter – glucose, effect of A 142
Teratogenesis *[see also* Embryo; Embryopathy; Pregnancy*]*
– diabetes – vitamin E, protection by in rat 1041
TGF *[see* Growth – factor – transforming*]*
Thalassaemia *[see* Iron*]*
Thermogenesis – leptin, effect of A 59
Thiazide – diabetogenesis – K^+_{Ca} channel 861 r, 865 r
Thioctic acid *[see* Lipoic acid*]*
Thrombocyte *[see* Platelet*]* A 55
Thyroid – hormone – T_3 – GLUT4, effect on A 172, A 173
Time domain analysis *[see* Heart – ECG*]*
Tolrestat *[see* Aldose – reductase – inhibitor*]*
Tonsillitis – chronic – diabetes – oxidative stress A 141
Transcription factor – IPF-1 A 108
– IUF-1 – nesidioblastoma cell A 126
Transcription factor – NF-kB – activation by glycation products A 22
Transferrin – urine – diabetes A 291
Transplantation *[see also* Cyclosporin*]*
– insulin-secreting cell – reinnervation 54
– islet *[see also* B-cell, islet – differentiation; Islet – differentiation*]* A 19, A 20, A 133–A 135
– – diabetic nephropathy, effect on – rat A 305
– – function – dog 37
– – immunoprotection – hollow fibres 523
– – nerve advanced glycation end-products, effect on A 138
– – reinnervation 54
– – study group (AIDSPIT) *EASD News Section 9/96* 35 w
– – xenograft 523
– kidney – ambulatory blood pressure monitoring A 290
– pancreas A 130–A 132
– – complications of diabetes, effect on 1415 r
– – failure – diabetic neuropathy, effect on A 259
– – functional outcome 462
– – hypoglycaemia awareness following A 58
– – insulin secretion A 19
– – quality of life, effect on 1415 r
– – study group (AIDSPIT) *EASD News Section 9/96* 35 w
– – systemic venous drainage – atherogenesis 1276
Transporter associated with antigen processing *[see* TAP*]*
Trial – randomised controlled – diabetes A 193
Triglyceride – serum – LDL particle size, effect on 453
Tumour necrosis factor α – Type 1 diabetes – role in 1005 r
– – twins 60
– diabetic neuropathy 263
– insulin resistance, role in A 153
Twin study – diabetes – Type 1 – cytokines 60
Tyrosine – hydroxylase – gene – Type 1 diabetes 594
– kinase – adipocyte – vanadate, effect of 235
– phosphatase – IA-2 – autoantibody *[see* Antibody – IA-2*]*

U

Ubikinon *[see* Coenzyme – Q10*]*
UGDP (University Group Diabetes Program) Study 503 r
Ulcer, diabetic *[see* Foot*]*
Ultrasonography – colour Doppler A 285
– colour Doppler A 300
Uric acid – serum – diabetes A 291
Urine – bacteriuria – gestational diabetes A 204

V

Vaccination – Type 1 diabetes, effect on 500c
Vanadate – peroxo- – adipocyte, effect on 235
Vascular – calcification – diabetic autonomic neuropathy and A 254
– disease – peripheral – angiotensin converting enzyme and 696
– – peripheral – aspirin prophylaxis in diabetes 1402r, 1405r, 1407r
– permeability factor – mesangial cell, production by A 294
– reactivity – diabetes, in – metformin, effect of A 228
– – diabetic foot A 3
– – gliclazide, effect of – diabetic hamster A 232
– – insulin, effect of – microalbuminuria and A 302
– – – sympathetic nerve activity and 91
– – sulphonylurea, effect of 1562
– relaxation – diabetes, impaired in – free radicals, effect of A 240
Vasodilatation – insulin-induced – sympathetic nerve and 91
VCAM *[see* Adhesion – molecule – vascular*]*
Virus – encephalomyocarditis A 83
– entero – diabetes – Type 1 A 82
– Type 1 diabetes, role in – GAD65 sequence homology and 1318
Viscosity – blood *[see* Haemorrheology*]*
Vitamin – B – thiamine – endothelial protection 1263
– C *[see also* Ascorbic acid*]* – diabetic neuropathy, effect on – rat 1047
– D – islet, effect on A 124
– E – diabetic embryopathy, effect on 1041, A 19
Von Willebrand factor – diabetic neuropathy, in 336
– mortality in Type 2 diabetes and 1540

W

Waist-hip ratio *[see* Fat – distribution*]*
WHO (World Health Organisation)
– diagnostic criteria for gestational diabetes 1070
– Strategy for Prevention of Non-communicable Diseases 1247r
Wound healing – diabetes – β-1,3-D polyglucose A 234

Z

ZMP (AICA ribotide) 1148